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Abstract
RNA virus persistence in lymphocytes has been studied extensively in vitro but
the influence of lymphocyte homeostatic mechanisms and antiviral immunity on
persistence has not been well studied in an in vivo system. It is demonstrated here that
vesicular stomatitis virus (VSV), a negative-strand RNA virus , is maintained in B
lymphocytes in vivo despite the existence of homeostatic mechanisms that drive the cells
to proliferate under conditions of B cell deficiency and a strong antibody response to the
virus. It is also shown that antiviral antibodies inhibit VSV reactivation from persistently
infected primary B cells in vitro. A model is proposed for virus persistence in vivo 
which B cell homeostatic signals drve virus expression in some infected cells , resulting
in an antibody response , which maintains virus persistence in B cells.
In the course of conducting experiments to define the homeostatic signals that
might act on persistently infected B cells in vivo it was found that a fraction of small
resting splenic B cells proliferates after adoptive transfer into B cell deficient hosts
(sublethally irradiated xid or SCID). This process, termed homeostatic proliferation , is
driven by B cell deficiency since proliferation is limited in B cell sufficient hosts. This
reveals the existence of a mechanism by which B cells sense their own numbers. The
proliferation is unique in that the replicating cells do not upregulate cell surface markers,
such as CD25 and B7- , associated with antigen or mitogen induced proliferation. They
, however, show transient increases in other activation markers (CD69 , CD71),
demonstrating the action of an inductive signal. Homeostatic proliferation is a property
of both mature and immature B cells , but in competition experiments, only mature B cells
Vll
inhibit proliferation. xid B cells express a defective form of Bruton s tyrosine kinase
(Btk); as a result, these cells proliferate poorly in response to stimulation through a
number of cell surface receptors including the BCR, IL- , IL- lOR, the toll-like receptor
RP- 105 , and CD38. Homeostatic proliferation is severely reduced in xid B cells; thus,
this process is regulated by a Btk-dependent inductive signal, which is counterbalanced
by an inhibitory signal provided by mature B cells. B cell homeostatic proliferation does
not rely on transcription factors (c-rel and p50) critical for conventional proliferation
induced by antigen or mitogen (c-rel), or for peripheral B cell survival (p50), suggesting
that multiple signals drve this process and that survival and proliferation signals are not
identical.
VSV persists in small , resting primary B cells for several weeks in vitro and virus
replication is restricted at multiple levels depending on the activation state of the cells.
After adoptive transfer of infected B cells into B cell deficient (xid) recipients, viral
RNA , but not infectious particles , can be detected by RT -PCR in recipient spleens for at
least 72 days. RT-PCR analysis ofFACS sorted donor cells stained with CFSE reveals
that viral RNA is maintained in transferred B cells but can also found in recipient cells.
Infected B cells can undergo homeostatic proliferation and an antibody response is
generated to the virus , suggesting that homeostatic signals induce virus expression in
some transferred cells. Virus persistence is maintained despite an active immune
response to the virus. In fact, persistence may be maintained by antiviral antibody since
in vitro treatment of infected primar B cells with anti-VSV antibody inhibits virus
reactivation at multiple levels (transcription , protein synthesis, assembly/release of
V11
infectious paricles). This inhibition is reversible upon antibody removal , demonstrating
that functional virus is maintained in antibody treated cells. Antibody specific for a
single viral protein (VSV G) is sufficient since inhibition is mediated by monoclonal
antibodies specific for a VSV G; neutralizing activity is not required because inhibition
occurs with non-neutralizing monoclonal antibodies to VSV G. It is proposed that
antibody binding to VSV G on infected B cells generates inhibitory signal(s) that
suppress signaling pathways required for virus replication in B cells. Finally, a model of
RNA virus persistence in B cells is proposed in which lymphocyte homeostatic signals
promote virus expression, leading to the production of antiviral antibodies, which
suppress virus replication inside infected B cells and help to maintain persistence.
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Chapter I
Introduction
Establishment of persistent infections is a property of many RNA and DNA
viruses. Persistent infections are generally characterized by the maintenance of viral
genomes in a non-infectious form (latent infection) or continuous production of virus
through non-cytolytic replication in host cells (chronic) (1). Herpes simplex virus (HSV)
is a double-stranded DNA virus that productively infects epithelial cells but establishes
latent infection of neurons; viral DNA is maintained, but no infectious virus is produced
and the only viral transcripts seen are the latency-associated transcripts (LATs) (1).
Infections of this kind are associated with periodic reactivatil?n of infectious virus from
latently infected cells, resulting in disease. This example ilustrates two strategies by
which viruses establish persistence; diminished viral gene expression in certain cell types
and infection of immunologically privileged tissues such as neurons (2). Chronic
infections , on the other hand, are associated with the continuous shedding of low levels of
virus over the lifetime of the host. Lymphocytic choriomeningitis virus (LCMV) is a
single-stranded RNA virus containing two genome segments (3). Infection of neonatal
mice results in a chronic infection in which persistence is favored by a non-lytic
replication strategy as well as suppression of the immune response to the virus (2). 
some cases chronic production of viral antigens results in the formation of immune
complexes which can be deposited in sites such as the renal glomeruli , resulting in
disease (3). These two examples clearly show that multiple mechanisms can lead to
persistent infection. Elucidating these mechanisms is important for two reasons. First
persistently infected individuals are natural reservoirs for virus and can disseminate the
infection to others in the population. Second, persistent viral infections may also cause
recurrent or chronic disease in the host. Understanding how these infections occur may
lead to the development strategies to interfere with the establishment or maintenance of
persistence or to induce virus clearng from the host.
Despite the absence of overt cytopathic effects in persistently infected cells
, there
is strong evidence that such infections can result in alterations of cellular functions and
in some cases , disease. In the C3H/ST strain of mice, LCMV persistent infection is
associated with retarded growth as the result of non-cytolytic virus replication in growth
hormone producing cells in the anterior pituitary (4 , 5). This reduction in growth
hormone production is the result of specific inhibition of growth hormone transcription
by the viral protein NP (2). Boma disease virus (BDV) is a non-cytolytic , negative-
strand RNA virus which causes a persistent infection of the CNS in neonatally infected
mice (6). Such infections are associated with a number of behavioral changes and
developmental abnormalities of the CNS including impaired learing abilties , loss of
spatial discrimination , and diminished taste (6-8). Taken together, these studies
demonstrate the potential for viruses that persist to subtly affect cellular function and
cause disease.
A common property of many viruses causing persistent infections is the ability to
infect lymphocytes , sometimes resulting in altered lymphocyte function leading to
immunodeficiency (9). Infections with measles virus , a negative-strand RNA virus have
long been associated with immunosuppression, and experimental infection of human
lymphocytes with this virus inhibits lymphocyte proliferation, NK cell activity and
secretion of immunoglobulin without affecting cell viabilty (9 , 10). Suppression of B
cell proliferation and antibody secretion is a direct effect of measles virus infection of B
cells , and may be the result of measles nucleocapsid protein binding to Fc receptors on B
cells (11 , 12). Measles virus infection of T cells does not affect cytokine secretion , but
does inhibit T cell proliferation, by the impairment of IL-2 receptor signaling mediated
through Akt kinase (9, 13). There is evidence that interactions with the measles virus
glycoproteins F and H on infected cells inhibits proliferation in uninfected cells,
providing a mechanism by which a small number of infected lymphocytes could,mediate
general immunosuppression (14). Thus, measles virus can alter the function of infected
and uninfected lymphocytes without killng the cells. Another example of
immunosuppression associated with virus infection of lymphocytes is HIV, which
predominantly infects CD4+ T cells , but can also infect dendrtic cells and macrophages
(15). HIV infection gives rise first to functional defects in CD4+ T cells (reduced
proliferation in response to antigen or mitogen) which is followed by a depletion of these
cells over time; some of the proposed mechanisms for CD4+ T cell depletion are direct
cell killng by HIV, formation of syncytia with uninfected cells, immune clearance of
infected cells, and disruption of T cell homeostasis (16). Thus, immunodeficiency
associated with infection of lymphocytes with measles virus , HIV , and many other
viruses is well documented and of great medical importance.
It has been demonstrated that a number of RNA viruses , including poliovirus,
measles , influenza A , vesicular stomatitis virus (VSV), and lymphocytic choriomeningitis
virus (LCMV) can infect lymphocytes (9). The ability of RNA viruses, especially highly
cytopathic ones such as VSV, to persist in lymphocytes in vivo and the mechanisms
involved have not been established. VSV is an ideal virus for these types of studies
because its replication and persistence (in lymphocytes and other cell types) have been
well studied in vitro. VSV is a negative-strand RNA virus that causes a disease of great
economic importance in cattle and horses (17). The replication of VSV has been
reviewed elsewhere (17) and wil be briefly summarzed here. VSV encodes five proteins
, P, M, G, and L) which are found in the virion plus two proteins derived from a
second reading frame within the P mRA that are only found in infected cells (18 , 19).
Attachment occurs by binding of the viral glycoprotein (G) to phosphatidylserine on
target cells and virus enters cells by receptor mediated endocytosis; subsequently, the
entire viral replicative cycle occurs in the cytoplasm. Transcription and genome
replication are carried out by the RNA-dependent RNA polymerase (a complex ofL and
P proteins) carried in the virion. The template for transcription is the genomic RNA
complexed with nucleoprotein (N); transcription requires phosphorylation of P and is
downregulated by matrix (M) protein. The switch from transcription to replication of the
viral genome requires de novo synthesis of viral Nand P proteins. The N, P , and L
proteins then form ribonucleoprotein (RNP) cores, which associate with G protein at the
plasma membrane through interactions with M protein , followed by budding and release
of infectious particles.
VSV is generally considered to be highly cytolytic; however, persistence of the
virus , defined as a low level of virus replication in the absence of cytopathic effect, has
been demonstrated in cell lines such as baby hamster kidney ce ls and mouse L cells. In
these in vitro systems , restriction of virus replication and inhibition of cytopathic effects
occur by three mechanisms; generation of defective interfering (DI) paricles , generation
of viral mutants , and the induction of interferon. DI paricles carry genomes containing
significant deletions such that they only replicate in cells co-infected with wild-type
virus; furthermore, they interfere with replication of wild-type virus by efficiently
competing for viral replicative proteins (20). Persistence of VSV in cell lines can be
established by co-infection of cells with wild-type virus and DI particles; this limits wild-
type virus replication and minimizes cytopathology (21 , 22). Long term persistence of
VSV in cell culture also results in the appearance of temperature sensitive (ts) viral
mutants that may be important in maintaining persistence; such mutants can establish
..J
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persistence without DI particles, demonstrating that persistence does not absolutely
require DI paricles (23, 24). These ts mutants have a small plaque phenotype , and the
mutations generally fall within the polymerase gene (L) or matrx protein gene (M)
resulting in less efficient virus replication and the inability to cary out host shut-off
functions (24-27).
Host cell factors may also be involved in maintaining persistent infections with
VSV in vitro. Interferons are a class of cytokines known to induce an antiviral state in
responsive cells by restricting virus transcription , translation , and assembly of virus
partcles (28). Pretreatment of mouse L cells with interferon followed by infection with
VSV leads to a persistent infection characterized by chronic low level virus production
with limited cytopathic effect (25). Small plaque mutants and DI particles are also
generated in these cultures , suggesting virus replication is restricted by a combination of
interferon , viral mutants , and DI paricles (25). This idea is reinforced by the finding
that some DI paricles and ts mutants generated during persistent infections in vitro are
strong inducers of interferon (29 , 30). VSV in persistently infected cells seems to be
subject to constant selective pressures since genome sequences change constantly over
time; this suggests that persistence in these 
in vitro models is a result of continuous
evolution of the virus which favors the generation of less cytopathic varants (31). Thus,
in cell culture models, VSV replication and cytopathic effects can be controlled by a
combination of viral and host cell factors resulting in cultures that can be persistently
infected for years.
The studies described above have examined VSV persistence in cell lines that are
1.'1
normally fully permssive for virus replication. Persistence can also be established and
maintained in cell types that are nonpermssive for virus replication. A number of
viruses , including VSV, can infect resting lymphocytes, but virus replication is not
supported; antigen or mitogen stimulated lymphocytes , on the other hand, support full
virus replication (32-36). Thus, lymphocytes can act as conditionally permssive host
cells for viruses. Studies in this laboratory have shown that VSV can infect small, resting
primary splenic B cells, but no viral proteins or infectious parcles are produced and only
low levels of viral transcripts are detected (35 , 36). All stages of virus replication can be
induced by treatment of infected cells with B cell specific activators, and different B cell
activation pathways support different levels of virus replication (35, 36). For example,
treatment of infected B cells with IL-4 enhances viral mRA levels, but viral proteins
and infectious particles are not produced; treatment with PMA enhances viral protein
production while stimulation with anti-Ig+IL-4 makes B cells fully permssive for virus
replication, resulting in production of infectious virus (36). Signals for B cell
proliferation and differentiation are not required for virus replication because some
activator combinations such as PMA+IL-4 make B cells fully permssive for virus
replication without inducing cell proliferation or antibody secretion (36). Thus, virus
replication can be regulated at many levels in B cells, and the ability to produce
infectious virus identifies a stage of B cell activation not apparent by conventional assays
such as eH)TdR incorporation or antibody secretion. More recent studies have
demonstrated that VSV can be maintained in culture for weeks in small resting B cells
from bcl-2 transgenic mice (B/bcl-2 cells) with no viral proteins or infectious virus
produced; virus can be reactivated from these cells at any time after the initiation of
persistent infection by treatment with B cell activators (M. Schmidt, manuscript in
preparation). This demonstrates that an RNA genome can be maintained in the absence
of continuous virus replication; thus , RNA virus persistence can be maintained by
mechanisms other than the generation of DI paricles and virus mutants. During in vivo
persistent infections, the ideal host cell should have two properties: first, it should
maintain virus without expressing viral proteins so as to evade the host immune response;
second, it should have the ability to periodically produce infectious virus to maintain
persistence within the host and allow for the dissemination of virus to other hosts. Given
the properties of VSV infection of primary B cells in vitro it is proposed here that resting
B cells harbor RNA viruses such as VSV during persistent infections in vivo. 
It is also
proposed that signals involved in the maintenance of B cells (homeostatic signals) induce
virus expression in these cells while immune mechanisms suppress virus replication and
maintain persistence. In order to better understand how VSV infected B cells might be
maintained in vivo, it is important to understand how lymphocytes are maintained and the
role immune responses play in persistent infections.
Lymphocyte homeostasis refers to the maintenance of a relatively constant
number of lymphocytes in the periphery throughout life. It reflects a balance between the
production of cells in the primary lymphoid organs and the loss or expansion of these
cells in the periphery. This process is regulated at many levels by signals through the
antigen receptor and other molecules on the surface of lymphocytes. 
In the thymus
signals through the T cell receptor (TCR) mediate positive and negative selection, a
process by which T cells are selected for their abilty to recognize non-self peptides in the
context of self-MHC (37). In addition to selection in the bone marow , B cells are also
subject to a selection step in the periphery during the transition from immature to mature
B cells, which involves signals through the B cell receptor (BCR) (38). These selection
steps regulate the number of lymphocytes that are able to leave the primary lymphoid
organs and enter mature lymphocyte pools. Once lymphocytes become par of the long-
lived recirculating pool, survival of both Band T cells is an active process requiring
signals induced through lymphocyte interaction with environmentalligands that control
the expression of anti-apoptotic molecules (39, 40). These signals are delivered to
lymphocytes through their antigen receptors (41-43), and to B cells by other molecules
including CD40L, IL-4, and BAFF/Blys (44-46). Similarly, survival of naive T cells is
influenced by additional factors; primarly IL-7 and other Yc cytokines as well as 
co stimulation and TGF- (47-50).
Lymphocyte numbers in the periphery are also affected by the proliferation of
mature lymphocytes. Under lymphopenic conditions , naive T (51) and B cells (this
dissertation) can proliferate without signs of overt activation or termnal differentiation;
this process has been termed homeostatic proliferation. , T cell homeostatic proliferation
requires interactions between the TCR and peptide-MHC complexes as well as other
signals (52-58); in B cells this process is Btk dependent (this dissertation). Activation of
specific lymphocytes by antigen and co-stimulatory signals , resulting in expansion and
differentiation to effector function, also occurs during the course of normal immune
responses. Thus, a variety of mechanisms acting on lymphocytes 
in vivo alter their
physiology and possibly their abilty to support virus replication.
One example that ilustrates the interplay between lymphocyte homeostasis and
virus persistence in these cells is Epstein-Bar virus (EBV). EBV is a member of the
herpesvirus famly that establishes a latent infection of resting memory B cells in human
hosts (59-61). A model for EBV persistence in B cells in vivo is emerging which
proposes that the virus manipulates normal B cell activation and homeostatic signals to
establish and maintain persistence. While EBV infects all B cell subsets 
in vivo, the
pattern of viral gene expression vares depending on the differentiation state of the cell.
Naive B cells express the "growth program" which induces proliferation of these cells;
tonsilar memory and germnal center cells , on the other hand, express a more restricted
set of genes (EBNA1, LMP1, and LMP2); peripheral resting memory B cells express
only LMP2 (62). By the current model , EBV initially infects. naive B cells and expresses
a pattern of genes that promote proliferation and differentiation to memory cells thereby
establishing a persistent infection in these cells (62). Infected memory B cells may be
maintained by the action of LMP2a (63) through which survival signals are transmitted
(64). LMP2a also blocks BCR signaling by entering lipid rafts, and this may interfere
with signals that would otherwise lead to B cell activation and reactivation of EBV from
latency (65 , 66). Thus , EBV persistence may be maintained in resting B cells in vivo 
virally encoded proteins which promote survival of infected B cells and interfere with the
normal homeostatic or activation signals generated through the BCR. EBV persistence is
also controlled by the host immune response to the virus; it is proposed that productively
:fi
infected (activated) B cells are killed by CTL while latently infected resting memory B
cells are poor CTL targets (59 , 60). This idea is supported by the fact that
immunosuppression results in increased shedding of virus and increased incidence of
EBV-positive lymphomas (59). Thus, a combination of homeostatic controls imposed on
infected B cells by viral proteins and the adaptive immune response to the virus ensures
the maintenance of latently infected B cells. EBV is an example of a complex DNA virus
that encodes proteins which modify lymphocyte function to establish and maintain-virus
persistence in B cells. Simple RNA viruses such as VSV, on the other hand, do not
encode such regulatory proteins; they likely take advantage of the normal physiology of
lymphocytes and the immune responses of the host to establish and maintain persistence
in lymphocytes.
The immune response to viral infections has two potential outcomes: clearance of
virus from the host after acute infection or persistence; many RNA viruses establish and
maintain persistent infections by evasion or suppression of the host immune response
(67). Given the high mutation rate of RNA viruses (68), it is not surprising that these
viruses generate mutants invivo that escape recognition by neutralizing antibody or CTL,
resulting in persistence (69, 70). RNA viruses can also establish persistence by inducing
immunosuppression in the host. General immunosuppression after LCMV infection in
mice is mediated by immune destruction of cells important for the immune response such
as antigen presenting cells and CD4+ T cells (71). LCMV can suppress the immune
response to itself by exhaustion of antiviral CTL (72); it has also been proposed that
LCMV promotes persistence in par by infecting B cells producing virus-specific
neutralizing antibodies , resulting in their elimination by CTL and suppression of the
neutralizing antibody response (73). Thus, RNA viruses have evolved a number of ways
in which to evade or interfere with host immune responses in order to establish
persistence.
There is also evidence that immune mechanisms are actively involved in the
maintenance of virus persistence. Reactivation from latency by members of the
herpesvirus family such as cytomegalovirus (CMV) is associated with
immunosuppression; murine CMV is reactivated from latently infected mice after
depletion of CD4+, CD8+, and NK cells (74). Furthermore , CD8+ T cells restrict
expression of herpes simplex virus type 1 (HSV - 1) late proteins and infectious virus in
explanted , latently infected trigeminal ganglia without destruction of the cells (75).
- These studies demonstrate that cellular immune mechanisms can control virus replication
while sparng infected cells and thus have the potential to support viral persistence.
Persistent viral infections are often maintained despite the presence of virus
specific antibodies; studies by several groups suggest that antiviral antibody can facilitate
a persistent infection by stripping viral antigens from the surface of infected cells or by
restrcting virus replication inside infected cells (2). Treatment of measles virus infected
HeLa cells with measles immune serum results in removal of measles antigens from the
cell surface and renders the cells resistant to complement mediated lysis (76).
Interestingly, treatment of infected cell lines with measles antiserum or monoclonal
antibodies to measles HA protein results in downregulation of both externally and
internally expressed viral proteins (77-81). Antibody mediated inhibition of measles
virus mRA synthesis has been observed in a rat model of measles encephalitis and in
persistently infected neuroblastoma cells (82, 83). Antiviral antibodies have also been
shown to inhibit replication in neuronal cells infected with reovirus, Sindbis virus , and
herpes simplex virus (84-86). This form of immune inhibition is not restricted to cells of
neural origin since it has been observed in rubella virus infected human PBMC or
lymphoblastoid cell lines and measles virus infected macrophage cell lines (81 , 87).
These studies demonstrate the abilty of antiviral antibodies to act directly on cells
infected with RNA viruses (measles virus , Sindbis virus , reovirus , rubella virus) and
suppress replication at the levels of transcription, protein synthesis, and infectious virus
production without killng the cells. Thus , antibody dependent restriction of virus
replication may playa role in the establishment or maintenance of RNA virus persistence
in vivo.
In this dissertation , a model for studying the mechanisms by which an RNA virus
(VSV) persists in B lymphocytes in vivo is described. Persistence of VSV in primary B
lymphocytes in vitro has two important characteristics which can be extended to explain
the behavior of the virus in vivo. First, the virus can be maintained for extended periods
of time in resting B cells without production of viral proteins or infectious paricles (M.
Schmidt, manuscript in preparation); this implies that in vivo, the virus could evade the
immune response by infecting resting B cells. Second, reactivation of infectious virus is
always induced when resting B cells are driven to proliferate, but proliferation is not
absolutely required for production of infectious particles (36). Thus , virus expression
(the production of viral proteins or infectious particles) in B cells could be induced 
vivo by signals that maintain B cells (survival), signals that promote proliferation
(homeostatic expansion), or signals that promote proliferation and differentiation to
effector function (response to specific antigen). This is important because it provides an
opportunity for the virus to exit resting lymphocytes to maintain the pool of persistently
infected cells and to potentially disseminate infection to other hosts. The host immune
response to the virus also impacts persistence in vivo. In response to VSV infection, mice
generate an early T-independent neutralizing IgM response followed on day 7 by a T-
dependent neutralizing IgG response (88). While CD8+ T cells are generated in response
to VSV infection , they are not required for a protective immune response to the virus (89,
90). Infection is lethal in the absence of an antibody response, and passively
f..:u
administered neutralizing antibodies are sufficient for protection (90-94). Type I (a/
but not type II (y) interferons are also essential in controllng virus replication before the
onset of the antibody response (95, 96). Thus, VSV infection in mice is controlled by a
combination of type I interferons and neutralizing antibody, suggesting that these
immune mechanisms might playa role in the establishment or maintenance of a
persistent infection in vivo.
Based on this background information , the studies described here had four goals:
1) to demonstrate that B cells persistently infected with an RNA virus (VSV) could be
maintained in vivo for an extended time; 2) to better understand the mechanisms by
which normal peripheral B cell homeostasis is maintained; 3) to determne if homeostatic
signals can induce virus expression in B cells in vivo; 
4) to determne the role of antiviral
antibody in persistence of this virus in B cells. The experiments in Chapter III show that
naive peripheral B cells are capable of undergoing proliferation in B cell deficient hosts
(termed homeostatic proliferation) without adopting an effector phenotype; since B cells
that proliferate in vitro can support full VSV replication, this provides a mechanism by
which virus might be reactivated from persistently infected B cells 
in vivo. In Chapter IV
it is shown that VSV can be maintained in infected B cells 
in vivo in spite of these
, homeostatic signals and an antibody response to the virus. Furthermore, evidence is
presented that homeostatic signals acting on some infected B cells induce virus
expression , resulting in an antibody response to the virus. Finally, it is shown that
antiviral antibody can inhibit the reactivation of virus from persistently infected B cells 
vitro suggesting a mechanism whereby antiviral antibodies playa role in maintaining
RNA virus persistence in lymphocytes invivo. TheseJesults lead to a model of in vivo
persistence in which viral RNA is maintained in resting B cells; homeostatic signals drve
production of virus or viral proteins in some infected cells which results in an immune
response to the virus. Antiviral antibody, in turn , inhibits reactivation of virus leading to
the maintenance of persistently infected B cells. By this model , reactivation of an RNA
virus from resting lymphocytes can occur when antiviral antibody titers decay over time
and under conditions of immunodeficiency, when mechanisms such as homeostatic
proliferation are induced to restore lymphocyte numbers.
Chapter II
Materials and Methods
Mice
CBAIN x A.By female (normal), C57BL/6 CBA/Ca-bcl- transgenic , or CBA/-bcl-
transgenic (age 8-24 weeks) were used as sources of spleen cells and B cells. CBA/ x
A.By female (normal) or male (xid), CBA/Ca (normal), CBAI (xid), C57BL/6 , or
C57BL/6.scid mice (age 12- 16 weeks) were used as recipients. In some experiments
recipients were irradiated using a 137 Cs source (Gammacell , Toronto, Canada) 24-
hours before adoptive transfer. All mice were bred and maintained in the animal
facilties at the University of Massachusetts Medical School using stock mice obtained
from the National Cancer Institute (Frederick, MD) or Jackson Laboratories (Bar Harbor
ME). Mice expressing the human Ig-bcl-2 transgene , originally obtained from Dr. S.
Korsmeyer (Washington University, St. Louis, MO) (97), were produced as previously
described (98). C57BL/6. scid mice were generously provided by Drs. Dale Greiner and
Eva Tsuda, University of Massachusetts Medical School or purchased from Jackson
Laboratories (Bar Harbor, ME). CD40- mice were generously provided by Drs. Dale
Greiner and Nancy Philips , University of Massachusetts Medical School. IL- , IL-
and p50. mice were purchased from Jackson Laboratories (Bar Harbor
, ME). c-rer and
B6.xid mice were generously provided by Drs. Ranjen Sen and Joan Press , Brandeis
University. All animal care and procedures were cared out in accordance with the
Animal Welfare Act.
Virus stocks
VSV-Indiana (Salt Lake City subtype) was obtained from Dr. Trudy Morrson
(University of Massachusetts Medical School , Worcester, MA), and stocks were prepared
as previously described (35). B cells were infected with VSV at a multiplicity of infection
of 10-20. VSV ilG-HA was generously provided by Dr. Jack Rose, Yale University (99).
Cell preparation: B cell homeostasis experiments
Total spleen or lymph node (excluding mesenteric) cell suspensions were prepared by
gently pressing lymphoid organs between glass slides in BSS-BSA (0.3% w/v)
supplemented with 100 fLg/ml streptomycin , 10 fLg/ml penicilin, and 10 fLg/ml
gentamycin. B cell enrched spleen cell populations were prepared by treating pooled
spleen cell suspensions with anti-Thy 1.2 mAb (clone 11110) and mouse-adsorbed rabbit
complement as previously described (100). Small resting cells (either B cells , total
spleen cells or lymph node cells) were prepared by fractionation on a Percoll step
gradient (50 65, 75%) prepared in HESS. Purified B cells analyzed by flow cytometry
were 85-95% B220+
B lymphocyte preparation: Virus persistence experiments
Small B lymphocytes were prepared and cultured as previously described (35). B cell
enriched spleen cell populations were prepared as described above. For in vitro
persistence experiments, small resting B cells were prepared by fractionation on a step
gradient of Percoll (50 , 65, 75%) prepared in HESS. Purified B cells were 85-95%
B220+. For in vivo persistence experiments, small resting B cells were purified by
counter-current centrifugal elutriation, had a mean cell diameter of 6 jlm as determned
by Coulter counter analysis , and constituted 20-30% of input B cells.
Preparation of immature B cells
Spleen cell populations enriched for immature B cells were produced in auto-
reconstituting, sublethally irradiated donors as described by Allman and Cancro (132).
Briefly, spleen cells were taken from CBNCa or CBAlxA.By normal donors irradiated
12- 13 days previously with 550 rads of whole body irradiation. B cells were prepared by
anti-Thy1.2 and complement treatment followed by depletion of dead cells and
erythrocytes on 50:60% Percoll gradients and harvesting cells at the 50:60% interface.
Immature B cells prepared by this procedure were greater than 95% B220+, and
uniformly CD24 (HSA)hi , p130- 140 (493 and AA4. 1t, IgMhi, IgD
B lymphocyte culture and activation
B cells were cultured at 5-10 x 106 cells/ml in RPMI- 1640 supplemented with 10% FCS
(Gibco), 2 mM glutamine, 50 jlM 2-mercaptoethanol , 100 jlg/ml streptomycin , 10 jlg/ml
penicilin , 10 jlg/ml gentamycin, and MEM nonessential amno acids. The following B
cell activators were used: F(ab' )2 fragments of affinity purified rabbit anti-mouse F(ab'
1':
at lOjlg/ml and recombinant IL-4 at 100 U/ml; LPS (Escherichia coli 055:B5 Westphal
Difco); PMA (Sigma) and ionomycin (Sigma) were dissolved in DMSO at 1 mg/ml and
used at 10 ng/ml and 1 jlg/ml respectively. Proliferation of activated B cells was assayed
by eH)TdR (Amersham) incorporation. Triplicate samples of 2x10 cells/well in 96-well
microtiter plates were pulsed with 1jlCi/well eH)TdR for 6 to 8 hours. Plates were
i:1
harvested with a LKB (Wallac , Inc. , Gaithersburg, 1\) cell harester and counted on a
LKB Betaplate reader.
CFSE staining
Small resting lymphocytes or immature B cells were stained with the vital dye CFSE (5-
(and-6)-carboxyfluorescein diacetate , succinimidyl ester) (Molecular Probes (Eugene,
OR) as previously described (101). Briefly, cells were washed and resuspended in
serum-free PBS or Hanks ' Balanced Salt Solution (HESS) at 50x10 cells/ml and mixed
with an equal volume of 2JLM CFSE in PBS (lJLm CFSE final concentration). The cells
were then incubated at 37 C for 10 minutes with gentle shaking, and washed in HBSS-
BSA (0.3% w/v) twice. In virus persistence experiments , B cells were stained prior to
infection.
Adoptive transfer
Cells were washed twice in BSS-BSA (0.3% w/v), once in PBS , resuspended in PBS at
the appropriate concentration. Cells (0.5 ml) were injected via the lateral tail vein. 
I:'
some virus persistence experiments, extracellular virus was neutralized before adoptive
transfer by treating infected B cells with a 1: 1000 dilution of VSV immune serum at 
C for 20 minutes. Serum was produced by immunization of CBA/xA.By female mice
with 2x10 PFU ofVSV-SLC.
FACS analysis: B cell homeostasis experiments
Single cell suspensions made from the spleens of individual adoptive transfer recipients
were treated with Gey s solution to remove red blood cells and resuspended in ice-cold
FACS buffer (PBS , 3%FCS , 0.02% sodium azide). Cells were treated with anti-FcR
antibody (2.4G2) and stained with APC, PE, or Tricolor conjugated anti-B220 (RA3-
6B2), PE conjugated anti- (14V. 18), anti-B7- 1 (RM-2), anti-B7-2 (RMM- 1),
anti-CD25 (PC61.5.3), anti-CD71 (RI7217. 1.4), PE or APC conjugated anti-Thy 1.2 (CT-
TH1) (Caltag); PE conjugated anti-IgD (11-26) or anti-CD69 (H1.2F3) (Southern
Biotechnology Associates); PE conjugated anti-HSA (M1I69) (pharmingen).
Biotinylated goat anti-mouse IgM (FisherBiotech) or biotinylated anti-CD38 ( clone 92)
(PharMingen) were detected with streptavidin- Tricolor (Caltag) or streptavidin-
Cychrome (PharMingen). The p130- 140 differentiation antigen of immature B cells was
detected using a mixture of 493 antibody (102) produced from a hybridoma generously
provided by Drs. A.G. Rolink and F. Melchers, Basel Institute for Immunology, and
AA4. 1 antibody (103) generously provided by Dr. R. Gerstein , University of
Massachusetts Medical School. Biotinylated antibodies to 493 or AA4. 1 were detected
with streptavidin-Tricolor (Caltag) or streptavidin-Cychrome (PharMingen). After
staining, cells were washed with FACS buffer and fixed with 2% paraformaldehyde in
PBS before analysis on either a FACSCalibur or FACSVantage machine. In all
experiments, 100 000- 150,000 events were collected. Dead cells were excluded based on
forward and side scatter and data analyzed using FlowJo (Tree Star, Inc.
F ACS sorting: Virus persistence experiments
Separation of transferred infected CFSE+ B cells was performed by sorting on a F ACS
Vantage (Becton-Dickinson). CFSE+ (donor) and CFSE" (recipient) cell populations were
collected and were 60-88% and ::99% pure, respectively. The efficiency of donor cell
transfer was assessed by staining total spleen cell populations with APC conjugated B220
'. .
(Caltag) and determning the percentage of CFSE+ B220+ cells using FlowJo software
(Tree Star, Inc.
In vivo BrdU labeling and analysis
, '
Adoptively transferred cells were labeled with BrdU in vivo by administering 1
mg of BrdU in PBS i.p. immediately after adoptive transfer, and then feeding the
recipients BrdU continuously in their drnking water (1 mg/ml) for one or two weeks.
BrdU containing drinking water was shielded from light and changed every three days.
Single cell suspensions were made from the spleens of individual recipients and stained
for incorporated BrdU using the procedure of Lentz, et al. (104) which was modified by
using unlabeled anti-BrdU (Becton Dickinson) as the primary antibody and PE
conjugated rat anti-mouse IgG (Becton Dickinson) as the detecting antibody.
ELISA
Detection of VSV specific antibodies was performed essentially as described previously
(94). Briefly, 96 well polyvinyl chloride plates (Falcon) were coated with 5- 10 mg of
protein from VSV -SLC infected CHO cells in carbonate-bicarbonate buffer (pH 9.
overnight at 4 C. Coated plates were blocked with PBS- 1 % BSA for one hour at room
temperature. Serial three-fold serum dilutions were made in PBS- 1 % BSA, added to the
blocked plates , and incubated at room temperature for 2 hours. VSV specific antibodies
were detected by incubating the plates forlh at room temperature with biotinylated rat
anti-mouse k (Zymed), goat anti-mouse IgM (Fisher), or goat anti-mouse IgGl (Fisher) at
a 1 :2000 dilution followed by streptavadin-HRP (Zymed) at a 1 :4000 dilution for 1h at
room temperature. The substrate TMB (Sigma) was prepared as described by the
manufacturer then added to each well (50- 100 ml) and the plates incubated for 10-
minutes at room temperature. O.D. was determined at 370nm on a plate reader
(Molecular Devices), and ELISA titers calculated by determining the serum dilution
which gave the half-maximal O.
Antibodies: Virus persistence experiments
Normal mouse serum (NMS) was obtained from a pool of unimmunized 129
CBAlxA/J and CBAlxA.By mice maintained under SPF conditions (18 ml total
volume). Anti-VSV serum was obtained from CBAlxA.By female mice immunized
with 2x10 PFU of VSV-SLC, boosted on day 21 , and bled out on day 28; this serum was
combined at 1:1 with the pooled NMS to increase the total volume to 15ml. Sera from
normal or VSV immune mice were filter sterilized before storage at - C. Purified
antibodies or antibody fragments were prepared from NMS or anti-VSV serum. Briefly,
immunoglobulin was initially fractionated using a 50% ammounium sulfate cut , the
precipitate dialyzed against 50mM Tris pH 8. , 50mM NaCI , and loaded on a DEAE
column equilibrated in the same buffer. Immunoglobulin was eluted using a 50mM Tris
pH 8.0, 50mM-500mM continuous NaCl gradient, concentrated, then further purified on
a protein A column. F(ab' )2 and Fab fragments were made from purified anti- VSV Ig by
digestion with pepsin and papain respectively. Purified intact Ig, F(ab' )2 and Fab
fragments were further purified on a G-100 sizing column followed by a protein A
column to remove any intact immunoglobulin or contaminating Fc fragments. Anti- VSV
F(ab' )2 and Fab fragments showed no evidence of intact immunoglobulin when run on a
10% SDS-PAGE gel and stained with Comaissie blue. In some experiments , Fab
;\1
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fragments were spun in a Beckman airfuge before use to eliminate aggregates. Ascites
fluids containing the following monoclonal antibodies were generously provided by Dr.
Leo LeFrancois , University on Connecticut Health Science Center: 1E9 (Indiana specific
neutralizing anti- VSV G); 8E11F2 (Indiana specific non-neutralizing anti- VSV G);
5E4D8 (Indianalew Jersey cross-reactive, non-neutralizing anti- VSV G); lOG4 (anti-
VSV N). All monoclonal antibodies are IgG2a, K (105 , 106). In some experiments
ascites fluids prepared in our laboratory from the hybridomas IE9F9 or 8E11C9
(generously provided by Dr. LeFrancois) were used.
Antibody inhibition of virus reactivation from B cells in vitro
Small resting splenic B cells from bcl-2 transgenic mice were infected with VSV -SLC at
moi=lO , washed 2-3 times, then placed in culture at a density 5- lOx10 cells per ml with
anti- VSV antibody or control antibody (NMS , NMS Ig, or control ascites). Half of the
media in each culture was replaced every 3-4 days with media containing fresh antibody.
After 7-9 days , cells were washed three times with complete RPMI , counted, and placed
into culture with or without the following B cell activators: anti-Ig+ILA , LPS, or
PMA+ionomycin. Separate cultures were set up to monitor virus production (0.5x106
cells/ml), RNA (5x10 cells/ml), and protein (1x10 cells/ml). Virus production cultures
were frozen at - , while cells from RNA and protein cultures were counted
resuspended in RLT buffer (Qiagen) or cell lysis buffer (36) respectively, and stored at
Assay for infectious virus
For in vivo persistence experiments , tissues were homogenized in PBS and subjected to
one freeze-thaw cycle. The homogenate was then vortexed, spun briefly to pellet debris,
and a lO-fold dilution of the supernatant assayed for plaque formation. For in vitro
persistence experiments, seriallO-fold dilutions were assayed. Supernatants (200 ml)
were placed on CHO monolayers in 60mm dishes, incubated at room temperature for 30
minutes, and the monolayers overlayed with a 1:1 mixture of 2X RPMI and 2% agar.
Plaques were counted after incubation of the monolayers at 37 C for two days.
Protein analysis
Viral protein synthesis was analyzed by continuous labeling with eSS)methionine
(Amersham, SJ- 1515) for 3-4 hours , 18-24 hours after activation of infected B cells as
previously described (36). Viral proteins were immunoprecipitated using a high titer
rabbit anti- VSV serum specific for VSV G, N, and P proteins as previously described
(36). VSV proteins were analyzed by running 1x10 cell equivalents of protein on 10%
SDS-PAGE gels and visualized by autoradiography or on a Molecular Imager (BioRad).
RNA extraction
Total RNA was prepared from cells or tissues using the Qiagen RNeasy Total RNA kit as
described by the manufacturer.
Northern blot analysis
Total RNA (4/Lg or RNA from equivalent cell number.s) was separated on 1 
formaldehyde-agarose gels and transferred to Hybond N+ membranes for analysis.
Filters were prehybridized at 42 C overnight in 50% deionized formarde, IX
Denhardt , 1 % SDS, 5X SSC , lOmM EDTA , 50 mM NaP0 (pH6.7), 0.2 mg/ml yeast
tRNA , and 0.2 mg/ml denatured salmon sperm DNA. DNA probes for VSV M, G, and L
were made from restriction fragments by random primer labeling as previously described
(36). Filters were hybridized with a mixture of the VSV M , G , and L probes overnight at
C in prehybridization buffer. Filters were washed at least twice with O. lX SSC and
1 % SDS for 45 min at 50 C before exposure to fim or a phosphorimager screen.
RT-PCR
Analysis of RNA was also performed by RT -PCR. Contaminating DNA was removed
from RNA samples essentially as described previously (107). Briefly, 2 flg of RNA was
resuspended in 50 fll of a reaction mix containing Ix Promega M-ML V Reverse
Transcriptase Buffer (50 mM Tris-HCl pH 8.3, 75 mM KCI , 3 mM MgCI2, 10 mM
DTT), 0.5 mM of each dNTP, 20 U RNasin (Promega), and 1 U DNase (Promega).
Reactions were incubated at 3TC for 30 min and then 75 C for 5 min. A mix of 0. flg
of random primers (Promega) or 25flg of oligo dT primers (Promega) and 100 U M-
ML V Reverse Transcriptase (Promega) was then added, and the reactions incubated at
C for 10 min C for 1 h, and 65 C for 10 min. In some cases , antisense primers
specific for VSV G or VSV M (see below) were used instead of random primers or oligo
dT. One-tenth of each RT reaction was subjected to PCR amplification. The primers
used for PCR were as follows: VSV M external sense primer 5'
ATGAAGAGGACACTAGCATGG- , VSV M external antisense primer 5'
TCTGAAGTGCTCTGGTACATT-3' (397 bp product); VSV M internal sense primer 5'
CGAGCGCTCCAATTGACAAAT- , vsv M internal antisense primer 5'
TACCGCTGGAGTGGCCTTAG-3' (260 bp product); actin sense primer 5'
ATGGATGACGATATCGCT- , actin antisense primer 5'
A TGAGGT AGTCTGTCAGGT (571 bp product). PCR reactions were in 45 Jll volumes:
Ix Sigma Taq polymerase buffer (10 mM Tris-HCl pH 8. 50 mM KCl , 0.001 % gelatin),
5 mM (actin primers) or 4 mM (VSV M primers) MgCI2, 6.25 pmol of each primer,
and 0.2 mM of each dNTP. Samples were heated at C for 5 min, quick chiled on ice,
and 2.5 U of Taq polymerase (Sigma) added to each. Amplification was performed in an
MJ Research MiniCycler for 35 cycles: denaturation 93 C 30 sec , annealing 55 C 30 sec
extension 72 C 30 sec , final extension 72 C 10 min. Ten microliters of each reaction
were run in 2% agarose (NuSieve) gels in TAB buffer. Products were visualized by
ethidium bromide staining.
Chapter III
B Lymphocytes Undergo Homeostatic Proliferation
In B Cell Deficient Recipients
Introduction
Poorly understood homeostatic mechanisms maintain constant lymphocyte
numbers in naive animals. Homeostasis is an ongoing process as lymphogenesis in
primary lymphoid organs continuously provides naive lymphocytes to the periphery, and
although slowed by aging (108, 109), lymphocyte production continues for the life of the
individual. Understanding the mechanism of normal peripheral homeostasis wil
contribute new insights into disease processes , since autoimmunity, cancer, and
immunodeficiency are all associated with dysregulation of lymphocyte numbers. Central
to the notion of homeostatic regulation in the periphery are lymphocyte-intrinsic sensing
and response mechanisms that detect variation in the size of the total lymphocyte pool
and make compensatory adjustments to lymphocyte numbers through feedback
regulation. This sensing mechanism likely functions in a unique local microenvironment
and is lymphocyte subpopulation specific since Band T cell numbers are independently
regulated (110).
Naive lymphocyte numbers are controlled at the level of lymphogenesis and by
mechanisms regulating cell proliferation and survival in the periphery. Survival of both
Band T cells is an active process requiring signals induced through lymphocyte
interaction with environmentalligands that control the expression of anti-apoptotic
; ,
molecules (39 , 40, 111). These signals are delivered to lymphocytes through their
antigen receptors (41-43), and to B cells by other molecules including CD40L, IL- , and
BAFF/Blys (44-46). Similarly, survival of naive T cells depends on additional factors;
primarily IL-7 and otheryc cytokines as well as B7 costimulation and TGF- (47-50).
Competition between individual lymphocytes for ligands that promote survival is a major
regulatory control on lymphocyte numbers (100 , 110 , 112).
Peripheral lymphocyte numbers are also maintained by homeostatic proliferation;
cell division induced in lymphopenic hosts in the absence of overt antigenic stimulation.
Adoptive transfer of CD4 or CD8 T cells into T cell deficient hosts results in expansion
of the donor T cells , and, like survival , requires interactions between the TCR and
peptide-MHC complexes as well as other signals (52-58). The similarty in inductive
signaling has led to the proposition that homeostatic proliferation and survival are par of
a stimulatory continuum, with the intensity of signal being titrated by the number of
competing lymphocytes. In this model , when T cell numbers are reduced, access to the
ligand(s) promoting survival is increased and proliferation is induced (113). A recent
report showing homeostatic proliferation requires p56)Ck while survival does not
however, indicates that the interrelationship between these two processes is complex
(114).
The mechanisms that maintain the naive peripheral B cell pool are stil poorly
understood. While it is known that signals through the BCR affect mature B cell survival
in vivo (41), it remains to be determned whether other regulatory mechanisms are active.
Indeed , it seems reasonable to hypothesize that Band T cells use similar mechanisms to
P'''
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maintain peripheral homeostasis. In this report , we present direct evidence that both
immature and mature B cells proliferate in response to a B cell deficiency. This
replication is under homeostatic control since neither population proliferates extensively
in B cell sufficient hosts. Unlike antigen or mitogen induced stimulation , B cells that
proliferate display a naive antigenic phenotype , and do not progress to effector functions.
Homeostatic proliferation requires Bruton s tyrosine kinase (Btk) a cytoplasmic kinase
critical for B cell proliferation , upregulation of anti-apoptotic molecules , and maturation
(115). We also find that two members of the Re1l-KB family of transcription factors
Rel and p50, are dispensable for homeostatic proliferation. The requirement for c-Rel
in BCR and mitogen induced proliferation (116) ilustrates the distinction between
homeostatic and antigen/mitogen induced replication. Since p50 is required for B cell
survival in vivo (116), but not homeostatic proliferation , the signals promoting these
processes are distinct. These data suggest that homeostatic proliferation is an important
component of both Band T cell peripheral maintenance.
Results
Splenic B cells divide after adoptive transfer into B cell deficient, but not B cell
sufficient recipients
xid mice cary a mutation in Bruton s tyrosine kinase (Btk) which impairs full B
cell development, resulting in a marked reduction of mature B cells in the periphery (117,
118). This selective B cell deficiency provides the opportunity to assess the ability of
transferred normal B cells to sense and respond to a deficit in the mature B cell
compartment without having to manipulate the system with ionizing radiation , which
could induce pro-proliferative factors. Small resting norm;Jl splenic B cells were stained
with CFSE (101) to allow tracking and determnation of cell divisions, and adoptively
transferred into unirradiated normal or xid recipients. CFSE+ B cells were readily
detected in the spleens of xid recipients early after transfer (day 2), but little cell division
had occurred (Figure 1A). By day 14, however, a significant proportion (27%) of the
CFSE+ B220+ B cells in xid recipients had divided, with three divisions being readily
distinguished (Figure 1A). Our analysis likely underestimates the extent of cell division
because cells that have divided more than three times wil appear to be in the CFSE
negative gate and excluded from the analysis (Fig 1A). Homeostatic proliferation of the
transferred B cells was dependent on B cell deficiency since a significantly smaller
proportion (7.4%, pc(O.OOl) of the CFSE+ B cells divided in normal recipients by day 14
(Figure 1A and 1C). Analysis of replication at early time points showed that proliferation
was ongoing over the 14 day assay period (Figure 2 and data not shown).
In some experiments the fluorescence intensity of cells in the main CFSE+ peak
(presumably undivided cells) decreased between day 2 and day 14 (Figure 1A). This
could indicate that all the cells in this peak had divided or the loss of dye by the normal
turnover of intracellular proteins to which CFSE is covalently bound (119). To
distinguish between these two possibilities , BrdU was administered continuously for 14
days to xid recipients of CFSE labeled normal B cells. Thereafter, spleens were
harvested, cells permeabilized, stained for BrdU, and analyzed by FACS. Of the cells in
the brightest CFSE+ fraction , only 5% of the cells incorporated BrdU (Figure 1B),
whereas 98% of the cells in peaks with lower CFSE intensity did so. These results
clearly show that the mosUntense CFSE peak consisted of undivided cells while the
CFSE+ cells with lower fluorescence intensity had divided.
Homeostatic proliferation was also evident in normal irradiated (20. 1:11.0%) or
B6. scid (33.4:12.0%) recipients , indicating that xid (23.4:10. 8%) recipients were not
unique (Figure 1C). Furthermore , proliferation was apparently T-independent because
SCID mice contain very few mature T cells. The T independence of B cell homeostatic
proliferation was further confirmed by the finding that B cells from CD4. donors
replicate as well in irradiated CD4- recipients as they do in irradiated normal recipients
(see below). We conclude from these experiments that splenic B cells undergo
homeostatic proliferation in a T cell independent manner when transferred into a B cell
deficient environment.
Figure 1. Normal splenic B cells proliferate in B deficient , but not B sufficient recipients
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Figure 1. Normal splenic B cells proliferate in B deficient , but not B sufficient
recipients. A. 40x10 CFSE labeled small resting splenic B cells from normal donors
(CBA/Ca or CBA/xABy females) were transferred into xid recipients (CBA/ or
CBA/NxABy male). Spleen cells from individual recipients on day 2 or day 14 were
analyzed by flow cytometry. The gate drawn in each histogram shows the percentage of
B220+ CFSE+ cells that have divided. B. 20x10 CFSE labeled small resting splenic B
cells from normal (CBA/xABy female) donors were transferred into xid (CBAlxA.
male) recipients. Recipients were fed BrdU continuously in their drnking water for 14
days before sacrificing. Spleen cells were analyzed for BrdU incorporation on day 14 as
described in Materials and Methods. Results are representative of two independent
experiments. C. 20-40x10 CFSE labeled small resting splenic B cells from normal
donors (CBA/xABy female , or C57BL/6) were transferred into syngeneic recipients;
unirradiated normal (CBA/NxA.By female or C57BL/6, n=9); sublethally irradiated
(250R) normal (CBA/xABy female or C57BL/6 , n=21); unirradiated xid
(CBA/xA.By male , n=15); or unirradiated C57BL/6.SCID (n=6). The percent of B220+
CFSE+ spleen cells that have divided by day 10- 14 is shown :!SE. Results are from two
to seven independent experiments.
B cells that divide after adoptive transfer maintain a resting phenotype
Antigen or mitogen stimulation changes the cell surface antigen phenotype of
both Band T cells. Homeostatic proliferation in T cells differs from antigen induced
replication in that memory, but not other activation markers , are upregulated (54 , 56 , 58
120-122). Accordingly, we examined a collection of cell surface markers known to
change their expression pattern on antigen/mitogen activated B cells: IgD and CD38,
which decrease on mitogen activated cells (123, 124); IgM, which is lost on B cells
undergoing class switching (125); CD25 (IL-2Ra chain), CD43, syndecan , CD69, CD71
(transferrn receptor), MHC class IT , B7- 1 and B7-2 which are all upregulated (126 , 127).
CD69 is routinely used as an early lymphocyte activation marker, whereas CD43 and
syndecan are a late activation markers expressed on antibody secreting, but not naive B
cells (128 , 129).
We analyzed surface marker expression on the replicating and non-replicating
fractions of small resting normal B cells transferred into xid recipients before
proliferation had occurred (day 2), at the beginning of proliferation (day 4), and at later
times (day 9) after transfer. B cells analyzed less than 24 hours after transfer served as
the unstimulated baseline whereas B cells stimulated in vitro with anti-Ig+IL-4 were used
as activated controls. In anti-Ig+IL-4 activated cells , all of the markers selected for
analysis underwent the expected increases or decreases (IgD) in expression by 2 days in
culture (Figure 2 and data not shown). For transferred B cells, although division was
negligible on day 2 , there was a pronounced increase in CD69 expression on most of the
cells. Neither cell size nor other cell surface markers were affected at this time point. 
day 4 , B cells which had divided demonstrated increased forward scatter
, a slight
decrease in IgD , and expressed higher levels of CD71 , whereas CD69 had returned to a
baseline level and other markers were unaffected. In the non-dividing fraction , CD69
had also returned to a baseline level , and there was no noteworthy change in any of the
other markers analyzed. By day 9, divided cells were slightly larger by forward scatter
and all other markers had returned to baseline levels. The expression of other activation
markers , including MHC class II, B7- , IgM and CD38 , as well as syndecan, a marker for
differentiation to effector function, was unchanged at all times analyzed on both divided
and undivided cells (data not shown).
These data suggest that homeostatic B cell proliferation is distinct from antigen or
mitogen drven proliferation in that the cells undergoing replication maintain a resting
phenotype. The transient increase in CD69 expression suggested that a substantial
fraction of transferred B cells received some inductive signal upon transfer
, whereas
changes in forward scatter, CD71 , and IgD expression on divided cells may reflect
continued signaling in these cells. This signaling, however, is not sufficient to induce
differentiation to effector function.
Figure 2. B cells undergoing homeostatic proliferation maintain a resting phenotype
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Figure 2. B cells undergoing homeostatic proliferation maintain a resting phenotype.
20x106 CFSE labeled small resting splenic B cells from normal donors (CBAlxA.
female) were transferred into xid recipients (CBAlxA.By male). Recipients were
sacrificed on day 2 , day 4 , or day 9 after adoptive transfer and spleen cells were analyzed
as described in Materials and Methods. Results are representative of four mice for each
time point from two independent experiments. Histograms show CFSE fluorescence
intensity or expression of the indicated cell surface markers on CFSE+ B220+ donor cells.
The marker expression and forward scatter of CFSE+ B220+ donor cells on day 1 after
transfer was used as a baseline for comparng marker expression at later time points. The
forward scatter and surface marker expression of purified small resting splenic B cells
stimulated with F(ab')2 fragments of affinity purified rabbit anti-mouse F(ab' )2 (10 J!g/ml)
plus rIL-4 (100 U/ml) for two days is shown for comparson.
Mature and immature B cells undergo homeostatic proliferation
Our data clearly show that resting splenic B cells undergo homeostatic
proliferation. Splenic B cells are a heterogeneous assortment of developmentally distinct
subpopulations. In order to unambiguously demonstrate that mature B cells underwent
homeostatic proliferation , we used lymph nodes as a source of donor cells , since
immature and marginal zone B cells are absent and B- 1 cells are extremely rare (130
131). A typical experiment is shown in Figure 3A; donor B cells (B220+ ) from the
spleens or lymph nodes of normal mice divided after adoptive transfer into xid recipients
24% and 18% respectively, while donor T cells (Thy1.2+) from spleens or lymph nodes
did not, 7% and 5% respectively. Overall , the extent of cell division was similar in
lymph node B cells compared to those purified from the spleen (Figure 3B; 19.3:10.
versus 21.4:10.6%). The fact that T cells from the same innoculum did not divide
extensively in these T cell suffcient recipients confirmed that the expansion was
lymphocyte subpopulation specific. We conclude from these data that mature B cells are
capable of homeostatic proliferation in B cell deficient recipients.
To assess the capacity of immature B cells to undergo homeostatic proliferation
we isolated a highly enriched population of immature donor B cells from the spleens of
mice auto-reconstituting after sublethal whole body irradiation (132). In these mice all
peripheral B cell populations are depleted by irradiation; two weeks thereafter, the
spleens consist almost exclusively of newly emergent immature B cells (::95% pB 130-
140+ and HSAhi) (102 , 132). Purified, CFSE labeled immature B cells replicated as
extensively as mature B cells when transferred into xid recipients (36.2:12.9%, Figure 3C
versus 21.4::O. , Figure 3B). As was found for mature B cells (Figure 1), immature B
cells failed to replicate when transferred to normal unirradiated recipients (5.7:!2.2%,
Figure 3C). Taken together , these data demonstrate that both mature and immature B
cells are capable of homeostatic proliferation in hosts deficient in mature B cells.
Figure 3. Homeostatic proliferation is a property of mature and immature B cells
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Figure 3. Homeostatic proliferation is a property of mature and immature B cells.
A. 20-40x10 CFSE labeled small total spleen or lymph node cells from normal donors
(CBAlxA.By female) were transferred into xid recipients (CBAlxA.By male) and
recipient spleen cells analyzed on day 14. Representative histograms demonstrating the
extent of cell division in CFSE+ donor B cells (B220+) and T cells (Thy 1. ) are shown.
B. Comparison of the extent of cell division in the indicated donor cell populations after
adoptive transfer into xid recipients. Results were compiled from 10 recipients in each
group from three independent experiments and are shown as percent divided:t SE. 
Pure populations of transitional B cells were prepared from normal donors
(CBAlxA.By female) as described in Materials and Methods. 25x10 cells were
adoptively transferred into either unirradiated normal (CBAlxA.By female) or xid
(CBAlxA.By male) recipients and analyzed on day 10 after transfer.
Mature, but not immature, B cells mediate feedback inhibition of homeostatic
proliferation
, '
Homeostatic proliferation is inhibited under conditions of lymphocyte sufficiency;
induced experimentally by transferring either high doses of homologous cells or using
normal recipients. Indeed, the extent of T cell homeostatic proliferation is inversely
related to the dose of transferred cells (121). Accordingly, we adoptively transferred
increasing numbers of CFSE-labeled purified splenic B cells to xid recipients to
demonstrate that susceptibility to competitive inhibition was also a property of peripheral
B cells (Figure 4A). There was clearly an inverse correlation between B cell dose and
the degree of homeostatic replication , with the least proliferation occurrng at the highest
cell dose. These differences were highly significant (p=0.03 to oeO.OOl), and demonstrate
that proliferation is limited by competition with other B cells. Likewise , inhibition was
demonstrated by transferrng increasing numbers of unlabeled normal splenic B mixed
with a constant dose of normal CFSE-labeled B cells (Figure 4B). In contrast, competing
xid B cells had no inhibitory effect (Figure 4B). Whether this reflects competition
between B cells for environmentalligands that drive proliferation or direct B cell:B cell
interactions that suppress proliferation is unknown.
We find that immature B cells replicate upon transfer to xid recipients , despite the
fact that xid mice have normal numbers of immature and marginal zone B cells. This
suggests that all B cells may not be subject to the same negative regulation or the
susceptibility to inhibition is developmentally acquired. The finding that immature B
cells transferred into normal recipients show significantly reduced replication , however
suggests that they are subject to regulati , but not by the homologous B cell
subpopulation. To determine if homeostatic proliferation of immature B cells could be
autoregulated in a subpopulation specific manner, graded doses of immature B cells were
transferred into xid recipients. In striking contrast to the behavior of mature B cells
homeostatic proliferation of immature B cells was equivalent at all cell doses transferred
(10 , and 90 millon cells, Figure 4C). These data indicate that mature B cells playa
central role in peripheral homeostasis by regulating their own homeostatic proliferation
and that of their immediate precursors.
If.
Figure 4. Mature , but not immature B cells inhibit homeostatic proliferation
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Figure 4. Mature , but not immature B cells inhibit homeostatic proliferation. A. The
indicated numbers of CFSE labeled small resting splenic B cells (mature B cells) from
normal donors were transferred into xid recipients and recipient spleen cells analyzed on
day 12. The percent of B220+ CFSE+ cells that had divided :t SE is shown. Gates were
set to only look at one cell division to avoid the inclusion of background CFSE" host cells
at the lower cell doses. Results of two independent experiments were averaged, n=9-
mice per cell dose. B. 15x10 CFSE labeled small resting splenic B cells from normal
donors were mixed with the indicated numbers of unstained normal or xid splenic B cells,
transferred into unirradiated xid recipients, and analyzed on day 13 after transfer.
0!p::0.3; *p.:0.04; **p.:O.Ol. C. The indicated numbers of purified immature B cells
were transferred into unirradiated xid recipients and analyzed on day 10.
B cell homeostatic proliferation does not require signals from CD4+ T cells
CD40 is expressed on naive mature B cells , and signaling through this receptor 
vitro induces B cell proliferation; the ligand for CD40 (CD40L) is expressed on activated
CD4+ T cells (133). IL-4 and IL-6 are cytokines that are secreted by activated T cells; IL-
4 promotes B cell proliferation in combination with other signals (such as anti-
immunoglobulin) while IL-6 promotes B cell hybridoma growth and the differentiation of
antigen stimulated primary B cells (134 , 135). Since signals through CD40 or signals
generated by IL-4 or IL-6 have the potential to promote B cell proliferation or
differentiation , we wanted to determne if these signals are involved in drving
homeostatic proliferation. Accordingly, CFSE labeled small resting B cells from wild-
type (B6) or CD40- mice were transferred into irradiated wild-type or IL- recipients;
wild-type B cells were also transferred into irradiated IL- recipients. Thus , the mutant
donor B cells lacked CD40 expression (136), and the mutant recipients were unable to
produce IL-4 or IL-6 (137, 138). Wild-type and CD40- B cells proliferated to the same
extent after transfer into irradiated B6 mice (Figure 5A , 21.1:11 % vs. 19.7:11.5%).
Similarly, wild-type B cells replicated at similar levels in irradiated B6 (21.1:11 %) IL-
(18.3:11 %), or IL- (23. 8:10.7%) recipients (Figure 5A). Compared to wild-type B cells
transferred into irradiated B6 recipients , however, proliferation was slightly reduced upon
transfer of CD40- B cells into IL- recipients (Figure 5A , 21.2:11 % vs. 16.7:10.7%),
suggesting that a combination of CD40 and IL-4 signals might play some role in this
expansion. This combination of signals was not absolutely required, however, because
the proliferation of CD40. B cells in IL- recipients was higher than that seen upon
transfer of wild-type B cells into unirradiated normal recipients (Figure 1 , 1O:t0.6%).
This demonstrated that there was no absolute requirement for CD40 , IL- , or IL-6 in B
cell homeostatic expansion.
Since CD40L, IL- , and IL-6 are expressed on or secreted by activated CD4+
cells (133- 135), these data suggested that CD4+ T cells were not involved in drving B
cell homeostatic proliferation. To test this idea directly, B cells from CD4. . mice which
lack CD4+ T cells (139), were transferred into irradiated wild-type (B6) or CD4.
recipients. The extent of homeostatic proliferation was not diminished in the absence of
CD4+ T cells, demonstrating that these cells are not required for proliferation (Figure 5B
B6--::irrad B6 , 22.7:t0. 7% vs. CD4- ::irrad CD4. 23. 8:t0.2%). Taken together, these
data demonstrate that the inductive signal(s) drving B cell homeostatic expansion are not
delivered by CD4+ T cells.
Figure 5. B cell homeostatic proliferation does not require signals from CD4+ T cells
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Figure 5. B cell homeostatic proliferation does not require signals from CD4 + T cells. 
20-25x10 CFSE labeled small splenic B cells from wild- type (C57BU6) or CD40-
donors were transferred into irradiated (250R) wild- type(C57BU6), IL- or IL-
recipients and analyzed on day 14 as described in Materials and Methods. The mean
percent divided:t SE in each donor cell population , gated on CFSE+ B220+ cells. Results
are from one to two experiments for each donor cell group. IL- recipients, n=3; all
others n=6- 15. B. 20x106 CFSE labeled small splenic B cells from wild- type (C57BU6)
or CD4- mice were transferred into irradiated (300R) wild-type or CD4- recipients and
analyzed on day 13 as described in Materials and Methods. CD4- B cells were also
transferred into unirradiated CD4. mice. The mean percent divided :t SE in each donor
cell population , gated on CFSE+ B220+ cells; n=4 per group.
Btk is involved in signaling pathways for B cell homeostatic proliferation
B cells are capable of homeostatic expansion in a B cell deficient environment
but the inductive signals are unknown. The critical role of the BCR in B cell survival
suggests that it may also playa role in homeostatic proliferation. Similarly, it has been
established that TCR signals are critical for survival and homeostatic proliferation (42
53- , 140). xid mice have a defect in Btk, a Tec family tyrosine kinase that is
involved in numerous signaling pathways in B cells (115). As a result, xid B cells
proliferate poorly in response to stimulation through a number of cell surface receptors
including the BCR, IL- , IL- lOR , the toll-like receptor RP- 105, and CD38 (141- 145).
The poor proliferation seen in vitro following stimulation through these receptors
led us to hypothesize that the signaling defects in xid B cells might render them less
responsive to the in vivo signals that drve homeostatic expansion. We examined this
possibility by comparing the replicative ability of normal and xid B cells after transfer
into xid recipients. We found that splenic xid B cells underwent significantly less
homeostatic proliferation than normal B cells (Figure 6A; 12.2:!1.1 % versus 24.3:!1.1 %,
p.-O. 001). To exclude poor survival of xid donor cells (146 , 147) as a basis for this effect,
we transferred splenic B cells from xidlcl- transgenic mice into xid recipients. B cells
from xidlcl- transgenic mice are enriched for mature IgM IgDhi B cells, have
enhanced survival in vitro, but remain refractory to stimulation with Btk dependent
activators, including anti-Ig (146). As with non-transgenic cells, xidlcl- transgenic B
cells showed significantly reduced homeostatic proliferation compared to normal bcl-
transgenic B cells (Figure 6A; 1O.9:!0.3% versus 23.7:!0.7%, p.-0.001), demonstrating
that the lack of proliferation was not due to reduced donor cell survival. Splenic
populations from xid mice have a higher proportion of immature B cells than normal and
it is possible that the most developmentally mature xid B cell is capable of homeostatic
proliferation. To look directly at the behavior of these cells , we used lymph node B cells
as the donor population in transfer. experiments. As was found with spleen cells, lymph
node xid B cells have a significant defect in homeostatic proliferation compared to
normal lymph node B cells (Figure 6A; 11.9:!O.9% versus 19.3:!O. , p.cO.OOl). These
results are consistent with the data from xidlcl- transgenic donors, which have
increased numbers of mature splenic B cells relative to non- transgenic xid mice.
We noted that homeostatic proliferation was not completely suppressed by the
Btk mutation in the strains tested. This could be due to the fact that the severity of the
Btk mutation is effected by genetic background (148). To test this possibilty, we
transferred B6 or B6.xid congenic B cells into B6. scid recipients. Under these
experimental conditions, reduced homeostatic proliferation of xid B cells was again
observed (Figure 6B; xid 5:!O. 2% versus normal , 33.4:!1.4% , p.cO.OOl), showing that
restricted xid replication is not an unexpected consequence of transferrng into an xid
environment. It is also noteworthy that replication of normal cells is highest in SCID
recipients (see Figures 1 , 6, and 7) and that the inhibition of replication of B6.xid B cells
is more prominent. Taken together, these data demonstrate that Btk-mediated signaling is
important for B cell homeostatic proliferation.
Figure 6. Reduced homeostatic proliferation of xid B cells
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Figure 6. Reduced homeostatic prolieration of xid B cells. A. 20x 1 0 CFSE labeled
small splenic B cells from' normal (CBNCa), normal/bcl- transgenic (NTG), xid
(CBA/), or xid/bcl- transgenic (XTG) donors were transferred into xid recipients
(CBA/) and analyzed on day 12 after transfer as described in Materials and Methods.
In other experiments 40x10 CFSE labeled small total lymph node cells from normal or
xid (CBA/xA. By female or male) donors were transferred into xid (CBAlxA.By male)
recipients and analyzed on day 14. The mean percent divided:t SE in each donor cell
population , gated on CFSE+ B220+ cells. Results are from one to two experiments for
each donor cell group, n=4- 11. p-:0. 001 compared to normal B cells. B. 20x10 CFSE
labeled small splenic B cells from normal (C57BL/6) or xid (C57BL/6.xid congenics)
were transferred into C57BL/6.SCID recipients and analyzed on day 12 after transfer.
C57BL/6 , n=9 (three experiments); C57BL/6.xid n=4 (one experiment). p-:0.001
compared to normal cells.
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Bcells from c-rer . or nfkbl- . mice are capable of homeostatic proliferation
Ligand-receptor interactions leading to cell proliferation require the upregulation
or relocalization of transcription factors. For B cells , optimal mitogen and antigen
induced replication requires members of the NF-KB/Rel family of transcription factors,
some of which act downstream of Btk (149 , 150). Targeted mutation of the c-rel gene
has demonstrated that c-Rel is important for B cell proliferation induced by stimulation
through the BCR, CD40 , and Toll receptors; but its absence does not affect peripheral B
cell numbers or survival in vivo (116 , 151). In contrast, loss of NF-KB1 (p50 , p105) has
little effect on proliferation induced by BCR cross-linking, however, survival of
peripheral mature B cells is severely compromised (116 , 152). These observations led us
to hypothesize that c-Rel or NF-KB1 knock-outs could be used to distinguish the signals
required for homeostatic proliferation from those necessar for mitogen and/or antigen
induced proliferation or peripheral B cell survival.
Small resting CFSE labeled spleen cells from B6 c-rel"/. or nfkb1 (p50)'/- mice
were adoptively transferred into irradiated (300R) B6 or unirradiated B6.SCID recipients
and the extent of homeostatic proliferation assessed on day 12 after transfer (Figure 7 A).
Clearly, lack of c-Rel or NF-KB1 expression had no effect on homeostatic proliferation in
B6.SCID (Figure 7B; B6, 39. 6:t1.3%; c-rel- 39.2:t3.4%; nfkbl"/- 54.3:t6. 1 %). Similar
results were obtained for c-rel"/- B cells in irradiated B6 recipients (B6, 30.8:t4. 1 %; c-rel"/-
27. 5:t2. , Figure 7B). The survival defect of nfkbr donor cells was exacerbated in
irradiated B6 recipients , so data could not be obtained for this group. The fact that
nfkb B cells proliferated on transfer (Figure 7 A ) but exhibited impaired survi val 
vivo (116) suggests that the signals involved in B cell survival and those for homeostatic
proliferation are not identical.
Although c-rel"/. B cells were unresponsive to anti-Ig+IL-4 or LPS stimulation 
vitro (data not shown), these cells had the same capacity for homeostatic proliferation as
did wild-type cells (Figure 7 A and 7B). These data suggest that the surface molecules
known to require c-Rel for proliferative responses (e.g. BCR, CD40 , Toll receptors) are
not exclusively involved in homeostatic proliferation , however it remains possible that
combined signaling using one or more of these molecules is important. In fact, it has
been shown that using a combination of mitogens that are individually inactive (anti-IgM
and LPS) can overcome the proliferative defects of c-rel"/. B cells(116). Overall , these
data demonstrate that survival and homeostatic proliferation are separable , and that
proliferation is optimally induced by a combination of signals.
Figure 7. B cells from c-rel- or p50- mice are capable of homeostatic proliferation
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Figure 7. B cells from c-rel'/- or p50. mice are capable of homeostatic proliferation. 
35x10 CFSE labeled, small resting total spleen cells from B6, c-rel'/- or p50- mice were
adoptively transferred into the indicated recipients. The percent of B220+ B cells in each
donor population was similar. Representative histograms showing the extent of
proliferation of CFSE+ B220+ cells on day 12- 13 after transfer. Survival of p50- cells in
irradiated recipients was poor, so the data are not shown. B. The mean percent divided :!
SE in each donor cell population , gated on CFSE+ B220+ cells. Results were averaged
from two independent experiments, n=6-8 mice per group.
Discussion
We show here that immature and mature B cells are subject to homeostatic
regulation in the periphery. B cells proliferate in response to a B cell deficient
environment in the host and replication is suppressed selectively in a cell dose dependent
fashion by mature B cells. B cells undegoing homeostatic proliferation fail to upregulate
antigenic markers induced on B cells responding to antigen or mitogen stimulation , and
this proliferation is independent of signals delivered by CD4+ T cells. While B cell
homeostatic proliferation depends on Btk mediated signaling, it does not rely on
transcription factors (c-Rel and p50) critical for conventional proliferation induced by
antigen or mitogen (c-Rel), or for peripheral B cell survival (p50), showing the
uniqueness of this inductive pathway. These data and the results of similar studies with T
cells suggest that homeostatic proliferation is a universal mechanism for effecting
peripheral lymphocyte homeostasis.
It was previously shown that CFSE labeled adult B cells replicated when
transferred to syngeneic neonatal, but not adult, recipients (101). The host age
dependence of B cell replication has also been shown in another model system (153). 
was not determned whether the B cells were responding to the selective
immunodeficiency of the neonatal host or a generalized stimulatory environment in
which lymphocyte replication is promoted. We have found that adult recipients readily
support B cell proliferation provided that mature endogenous B cells are reduced in
number. Although proliferation is limited in normal unirradiated recipients, it does occur
in xid recipients, which are deficient in mature IgM IgDhi cells (117 , 118); sublethally
ft ,
irradiated (250R) normal recipients , which are primarily B cell deficient (154), and SCID
recipients which are deficient in both T and B cells (155). This replication is specific for
the deficient subpopulation since xid mice have normal numbers of T cells. Moreover, B
cell replication is T cell independent since it occurs in SCID and CD4. recipients. The
finding that homeostatic proliferation is not completely absent in normal unirradiated
j .
recipients suggests that this phenomenon may be a normal component of peripheral B
cell homeostasis.
Homeostatic proliferation is a property of both immature and mature B cells.
Purified immature B cells from auto-reconstituting irradiated donors actively proliferated
in xid recipients. Mature B cells purified from lymph nodes , which do not contain
immature or marginal zone B cells, or B1 cells (130, 131), also actively proliferated.
When transferred into xid recipients, we observed that mature B cell proliferation was
inversely proportional to cell dose , while immature B cells proliferated equally at all cell
doses. Replication of immature B cells was suppressed after transfer into unirradiated
normal recipients showing their sensitivity to inhibition. While normal and xid recipients
have comparable numbers of immature and marginal zone B cells, normal mice have
significantly more mature B cells. Therefore, it might be reasonable to assume that there
is a sensing mechanism present that maintains normal B cell numbers within the host and
that the mature B cell is the dominant regulator of both immature and mature B cell
homeostatic proliferation.
An inductive signal is involved in homeostatic proliferation because we observe a
transient increase in CD69 on virtually every transferred cell. The cells that do divide
also show increases in forward scatter and expression of CD71 which return to resting
levels. This signal does not promote differentiation to antibody secretion, as shown by
the lack of CD43 and syndecan expression and the maintenance of CD38 , IgM, and IgD
expression on divided cells. It has been shown that T cells which divide in lymphopenic
hosts increase CD44 expression , a marker of memory cells , as well as other memory
markers such as Ly6C , CD122, CD132 , and LFA-l (53- 58). Memory marker
expression and increased antigen responsiveness were a function of an increased number
of cell divisions (120, 121). We can easily follow three cell divisions with B cells, and
these cells return to a resting phenotype. While we cannot exclude the possibilty that
cells which divide more than three times differentiate to effector function, our data are
consistent with the idea that B cells undergoing homeostatic proliferation receive an
inductive signal , but remain naive. Two pieces of evidence demonstrate that this
inductive signal is not delivered by CD4+ T cells. First signals delivered by CD40L, IL-
, or IL- , which are on the surface of or secreted by activated T cells (133- 135), are not
absolutely required for homeostatic proliferation. Second, B cells from CD4- donors
transferred into irradiated CD4- recipients proliferate as well as B cells transferred into a
CD4+ T cell sufficient environment. Thus, while the existence of an inductive signal is
clear, the nature of the signal remains unknown.
Our observation that xid and xid/bcl- transgenic B cells are defective for
homeostatic proliferation demonstrates that Btk is an important component of the
inductive signal(s) driving homeostatic proliferation. Based on the observation that T
cell homeostatic proliferation requires interactions between the TCR and peptide-MHC
---
- r
complexes (53-57, 156), it is tempting to speculate that signals through the BCR may be
involved in B cell homeostatic expansion. The Btk dependence of proliferation is
consistent with this idea, since xid B cells are hyporesponsive to anti-Ig stimulation 
vitro (141). xid B cells , however, also have defects in signaling through a number of
other cell surface receptors, including the IL-5 and IL- lO receptors (142 , 143), RP- 105
(144), and CD38 (145). Thus , we cannot rule out the possibility that these or other
molecules are involved in B cell homeostatic proliferation.
We also examined the effects of deficiencies in the NF-KB family members c-Rel
or p50 on B cell homeostatic proliferation. c-Rel is interesting because it is required for
B cell proliferation in response to a variety of mitogens, including anti-Ig (116 , 151).
p50 , on the other hand, is not required for mitogen induced proliferation , but is involved
in regulating B cell survival , since p50. B cells undergo more rapid apoptosis in vitro
and have faster turnover rates in vivo (116 , 152). Interestingly, we find that homeostatic
proliferation is not impaired in Rel'/- or p50. Bcells. While the c-Rel data would seem
to argue against involvement of the BCR in homeostatic proliferation , it has been shown
that the defect in anti-Ig induced proliferation can be parially overcome by combinations
of activators such as anti-Ig +LPS or anti-IgM+anti-CD40 (116, 157), so it is possible
that signals through the BCR along with other signals are involved. The p50- result
suggests that the signals involved in B cell survival and homeostatic proliferation are not
identical , which is consistent with recent data on T cells showing that homeostatic
proliferation, but not survival , was impaired in T cells lacking p561ck (114). This does not
exclude the possibilty, however, that these two processes use some common signaling
r:t
pathways. For example , survjval and homeostatic proliferation may both use the BCR,
with survival requiring one set of additional signals and proliferation another.
Overall , our data are consistent with a model in which immature and naive mature
B cells sense the number of mature cells in the periphery and respond to a reduction in
these cells by proliferating; this response is exaggerated in B cell deficient hosts. This
sensing mechanism may operate in a specific microenvironment since pertussis toxin
treatment of donor cells blocks entry into the splenic white pulp and inhibits B cell
proliferation and survival in neonatal recipients (158 , 159). A model depicting the
putative signals involved in drving homeostatic proliferation is shown in Figure 8.
Signals through the BCR and other receptors on B cells promote cell survival in vivo (41
44-46). Our observation that mature B cells mediate feedback inhibition of homeostatic
proliferation suggests that there is an inhibitory signal delivered by mature B cells that
normally suppresses proliferation. Under conditions of B cell deficiency, the inhibitory
signal may be removed and stronger survival signals delivered; in addition, other
receptors may be engaged that promote B cell proliferation without differentiation to
effector function.
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Figure 8. Model for B cell homeostatic proliferation. Signals through
the BCR and other receptors on B cells promote cell survival in vivo.
Furthermore , there may be inhibitory signals that prevent B cells from
proliferating in response to these signals. Under conditions of B cell
deficiency, stronger survival signals may be delivered, and other receptors
engaged that promote B cell proliferation without differentiation to
effector function.
Since our data with xid B cells are consistent with BCR involvement arid the
c-rel"/. and p50- experiments do not exclude it, we hypothesize that the BCR is one of the
B cell surface receptors involved in drving B cell homeostatic proliferation. There is
evidence for a single BCR specificity binding a number of peptide ligands , and these
ligands differ in their ability to activate B cells depending on the affinity of the
interaction (160). So , it is possible that mature B cells bind cross-reactive ligands with
low affinity in the periphery. Under conditions of B cell deficiency, these ligands might
be more readily available, leading to increased BCR signaling which contrbutes to B cell
proliferation. One prediction of this model is that B cells with different specificities
should undergo different degrees of homeostatic proliferation. In fact, it has been shown
that T cell homeostatic proliferation is dependent on the TCR specificity, since some
TCR transgenics fail to proliferate in lymphopenic hosts (55). We are currently testing
this hypothesis using Ig heavy chain transgenic mice.
Another possibility is that the BCR generates a low level signal without being
engaged by environmentalligands. In this model, the outcome of BCR signaling is
determined not by the degree of BCR cross-linking, but by the composition of the BCR
signaling complex. There are several proteins known to positively or negatively regulate
BCR signaling, and it is the balance between these proteins that determnes the outcome
of BCR signaling (161). One example is CD22 , which constitutively associates with the
BCRin resting B cells and is thought to inhibit spontaneous BCR signaling (162). This
idea is supported by the finding that sequestering CD22 away from the BCR using anti-
CD22 coated beads lowers the concentration of anti-IgM required to induce B cell
proliferation by 100-fold (163). CD22 binds Sia6LacNAc, a trisaccharide found in many
glycoproteins (161). Thus, one can envision a model in which CD22 is associated with
the BCR under B cell suffcient conditions; when B cell numbers decrease , more CD22
may be bound by its ligand and sequestered away from the BCR. This would lead to a
stronger " spontaneous " signal that might synergize with other signals to drive
homeostatic expansion. A knock-out for the enzyme that produces the ligand for CD22
(ST6Gal sialyltranferase) has been made, and these mice show defective humoral
immune responses (164). If sequestering CD22 away from the BCR is involved in
homeostatic proliferation , one would expect proliferation in irradiated ST6Gal
sialyltranferase knock-outs to be reduced.
B cells from c-Rel knock-out mice show impaired anti-immunoglobulin induced
proliferation , but this defect can be overcome using combinations of activator such as
anti-Ig+LPS (116). Assuming that BCR signals contribute to homeostatic proliferation
the observation that Rel"/. B cells are capable of replicating in B-deficient hosts suggests
that other factors are important as well. Alternatively, such signals might induce
proliferation independently of the BCR. If this is the case , these inductive pathways must
be Btk dependent; two possibilites are CD38 and RP105. CD38 is expressed on mature
B cells , and cross-linking this molecule in combination with IL-4 or LPS induces B cell
proliferation in a Btk dependent manner (145 , 165). Interestingly, stimulation through
CD38 does not induce nuclear translocation of c-Rel , suggesting that this pathway is not
Rel dependent (R. Woodland, laboratory observations). The fact that CD38 can induce
B cell proliferation in a Btk dependent, c-Rel independent fashion makes it possible that
this pathway is involved in B cell homeostatic proliferation. This hypothesis is testable
since a CD38 knock-out mouse has been developed (165). RP105 is a member of the
Toll-like family of proteins that is expressed on mature B cells and is involved in LPS
responses (144 , 166). Cross-linking this protein induces B cell proliferation in normal
but not Btk-defective xid B cells (144). Proliferation to anti-RP105 is also reduced in c-
rer and p50. B cells, but like BCR dependent proliferation in these cells, the defect can
be corrected by the addition of cytokines (I- , IL- , and IL-5) or LPS (116). This
suggests that signals through RP105 , possibly induced by bacterial cell wall components
such as LPS, might contrbute to the induction of homeostatic proliferation.
The induction of CD69 essentially all B cells transferred into xid recipients
suggests that an inductive signal drves proliferation in these hosts. The fact that mature
B cells suppress this proliferation indicates that an inhibitory signal in normally involved
in controllng B cell replication. Thus , a balance of positive and negative signals likely
controls this process. Interestingly, two receptors that are members of the TNF family
(BCMA and TACI) and are expressed on B cells in the periphery (167) have recently
been shown to provide both positive and negative regulatory signals to B cells. The
ligands for TACI and BCMA are BAF (also known as BLyS) and APRI, which are
expressed on or secreted by monocytes, dendrtic cells, and activated T cells (167). Both
BAF/BLyS and APRI can bind to either BCMA or TACI, but there may be
preferential TACI-BAF/BLyS and BCMA-APRI binding (168). A number of lines of
evidence suggest that this dual receptor-ligand system is involved in maintaining
peripheral B cell homeostasis. In vitro BAF/BLyS enhances B cell proliferation
induced by anti-immunoglobulin treatment (169, 170) nd also promotes the survival of
all B cell populations, including immature splenic B cells (171). The importance of
BAF/BLyS in peripheral B cell homeostasis is further demonstrated by in vivo studies;
BAFF transgenic mice show a large increase in the number of peripheral B cells while
blocking BAFF/BLyS receptor binding with soluble BCMA leads to a decrease in
peripheral B cell numbers (46 , 172). Thus , BAF/BLyS may maintain homeostasis by
promoting B cell survival and perhaps proliferation. Interestingly, TACI knock-out mice
have increased numbers of hyperproliferative B cells in the spleen , suggesting that T ACI
delivers inhibitory signals to Bcells in vivo. These data indicate that the BAF/BLyS-
TACI/CMA receptor-ligand system has the potential to mediate both positive and
negative signaling in B cells. A model can be envisioned in which preferential use of
T ACI under B cell sufficient conditions tends to suppress B cell replication while in a B
cell deficient environment, BAFF/BLyS binds BCMA to promote homeostatic
proliferation. Thus , it would be interesting to see if homeostatic proliferation is enhanced
by exogenous BAFF/BLyS or inhibited by soluble BCMA. Our data suggest that
multiple signals are involved in driving homeostatic expansion, and experiments such as
these should allow us to dissect out the important pathways.
The fact that we see a small degree of proliferation after adoptive transfer into
unirradiated normal recipients suggests that homeostatic proliferation occurs at a low
level and may contribute to normal B cell homeostasis. If, as we speculate , signals
through the BCR and BCR specificity are important for this process, homeostatic
proliferation may help to determine the naive B cell repertoire. The contribution of
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homeostatic proliferation to the repertoire would be greater during reconstitution of
immunodeficient hosts and perhaps in neonates. Finally, we have preliminar evidence
that the aged environment is less capable of supporting homeostatic proliferation. This
may in part explain the defects in B cell-mediated immunity and repertoire changes in
older individuals.
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Chapter IV
In Vivo Persistence Of Vesicular Stomatitis Virus In B Cells
And Suppression Of Reactivation By Antiviral Antibody
Introduction
Persistent virus infections are characterized either by the maintenance of viral
genomes in a host cell or organism in a noninfectious state or by continuous low level
production of virus after acute infection (1). Establishing persistent infections allows
viruses to evade the host immune response and thus be maintained within individuals in a
population of susceptible hosts; these types of infections are often associated with
diseases such as cancer, immunodeficiency, and disorders of the central nervous system
(1). Persistence of RNA viruses such as hepatitis C virus and measles virus has been
associated with chronic diseases including hepatitis, hepatocellular carcinoma and
subacute sclerosing panencephalititis (173, 174). Vesicular stomatitis virus (VSV) is a
negative-strand RNA virus of the Rhabdovirus family (17). Many studies of persistence
using RNA viruses such as VSV have been cared out in cell lines; the mechanisms of
persistence in these systems generally involve the restriction of virus replication in
nonpermissive cells, the emergence of viral mutants or defective interfering particles , and
the induction of antiviral factors, such as interferon, by infected cells (21- , 29, 30).
The mechanisms by which RNA viruses persist in vivo, however, are not well
understood.
One way in which a virus can persist in vivo is by infection of nonpermssive cell
types , which limits injury to the host and allows the virus to evade the immune response
(1). Lymphocytes act as conditionally permssive host cells for many viruses , including
VSV in that resting lymphocytes are non-permssive while antigen or mitogen stimulated
cells support full virus replication (32-36). Persistent infections are often characterized
by a cyclical pattern of virus replication: periods of little or no infectious virus production
followed by periodic production of higher levels of infectious virus. In vivo,
lymphocytes exist in a continuum of activation states, from resting cells to fully activated
effector cells; this allows them to harbor non-replicating virus or support full virus
replication in vivo.
When VSV infects small , resting primary splenic B cells , no viral proteins or
infectious particles are produced and only low levels of viral transcripts can be detected
(35 36). The full viral replicative cycle can be induced, however, by treatment with B
cell specific activators , with different B cell activation pathways supporting different
levels of virus replication (35 , 36). For example , treatment of infected B cells with IL-
enhances viral mRA levels , but viral proteins and infectious particles are not produced.
Treatment with PMA enhances viral protein production but does not support infectious
paricle production whereas anti-Ig+IL-4 makes B cells fully permissive for virus
replication (36). Signals sufficient to drve B cell replication and differentiation are not
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required for virus replication because activator combinations such as PMA+IL-4 make B
cells fully permissive for virus replication without inducing cell proliferation or antibody
secretion (36). Thus , submitogenic signals or signals that promote proliferation but not
differentiation may alter B cell permssiveness for VSV in vivo.
Mice expressing the anti-apoptotic protein Bcl-2 as a transgene under the control
of the Ig heavy chain enhancer have an expanded population of mature B cells in the
spleen (97). B cells from these mice (B/bcl-2 cells) show greatly extended survival in
culture (97 , 146), making them ideal for studying long term virus persistence in primary
lymphocytes in vitro. VSV is maintained in culture for weeks in small resting B/bc1-
cells with no viral proteins or infectious virus produced; infectious virus can be
reactivated from these cells at any time after the initiation of persistent infection by
treatment with B cell activators (M. Schmidt, manuscript in preparation). It is generally
thought that RNA viruses persist by low level , non-cytopathic replication in host cells
(1). VSV persistence in resting B cells , however, is more akn to latent infection caused
by DNA viruses such as EBV , which evades the host immune response by restricting
viral gene expression in resting B cells (59). Thus resting B cells may make an ideal
reservoir for maintaining in vivo, allowing the virus to evade the host immune response.
In vivo, however, B cells receive of variety of signals , which may alter their activation
state. B cells are actively maintained in vivo by signals delivered through the BCR and
other cell surface receptors (41, 44-46). Furthermore , it is shown in this dissertation that
B cells can be induced to proliferate without differentiation to effector function under
lymphopenic conditions (Chapter II). Since virus expression is dependent on the
activation state of lymphocytes, do these signals effect virus replication in infected B
cells? Homeostatic signals delivered to B cells may enable them to make infectious virus
or viral proteins. Infected B cells could be killed directly by the virus; alternatively, a
host immune response generated as a consequence of virus expression could clear
infected cells or help to maintain persistence
There is evidence to suggest that effector cells of the acquired immune response
to viruses are directly involved in maintaining virus persistence. Loss of T cells and NK
cells results in reactivation of murine CMV from latently infected mice and CD8+ T cells
inhibit reactivation of HSV- 1 from latently infected trigeminal ganglia (74 , 75). It has
also been suggested that antiviral antibody is directly involved in maintaining persistence
by stripping viral antigens from the surface of infected cells or by restricting intracellular
virus replication (2). Treatment of infected cell lines with measles antiserum or
monoclonal antibodies to measles HA protein results in downregulation of both
externally and internally expressed viral proteins (77-81). Restriction of measles virus
mRA by antibody treatment has also been observed in a rat model of measles
encephalitis and in persistently infected neuroblastoma cells (82, 83). These studies
demonstrate the ability of antiviral antibodies to act directly on cells harboring an RNA
virus (measles virus) and suppress replication at the levels of transcription, protein
synthesis, and infectious virus production without killng the cells. Thus , antibody
dependent inhibition of virus replication may playa role in the establishment or
maintenance of RNA virus persistence in vivo. VSV infection in mice is primarily
controlled by neutralizing antibody (90-94) and Type I (a/f3) interferons (95, 96),
suggesting that these immune mechanisms might playa role in the establishment or
maintenance of VSV persistence in vivo.
Three questions are addressed in this chapter: 1) can VSV infected B cells be
maintained in vivo for an extended period of time? 2) can virus be reactivated from
persistently infected B cells in vivo? 3) does antiviral antibody playa role in maintaining
virus persistence in B cells? In order to address these questions , two experimental
approaches were taken. Persistence of VSV in B cells in vivo was studied by purifying
small, resting splenic B cells, infecting them with VSV , and adoptively transferrng them
into naive recipients. This approach has the following advantages: the cell type of
interest (B cells) is specifically targeted for infection; large numbers of infected cells can
be transferred making detection of infected cells easier; the cells can be tracked in vivo 
staining with fluorescent dyes. The effect of antiviral antibody on VSV persistence and
reactivation in primar B cells was studied in an in vitro system using B cells from bcl-
transgenic mice. VSV infected, bcl-2 transgenic B cells can be maintained for weeks in
culture; this allows one to determne the effects of long term antibody treatment on the
maintenance of virus persistence in primar B cells.
These experiments demonstrate that VSV can be maintained in B cells for at least
72 days after adoptive transfer. An antibody response to VSV is seen in infected B cell
recipients which is concurrent with the proliferation of a fraction of the transferred cells;
this suggests that signals inducing homeostatic proliferation may induce virus expression
in some infected B cells. Viral RNA can be detected in the spleens of infected B cell
recipients , but infectious virus cannot be isolated from activated spleen cells , in icating
that virus replication is suppressed in these animals. In vitro prolonged treatment of
VSV infected , bcl-2 transgenic B cells with anti- VSV antibody results in suppression of
viral RNA , protein , and infectious paricle production after removal of antibody and
stimulation of infected cells; however, virus can be reactivated from antibody treated
cells after culturing the cells in the absence of antibody. Taken together, these
observations lead to a model of VSV persistence in B cells in vivo in which viral genomic
RNA is maintained in resting B cells, resulting in evasion of the immune response. Virus
expression may be induced in some cells by homeostatic signals that drve proliferation
resulting in an antibody response to the virus. The antiviral antibody, in turn, suppresses
virus reactivation and maintains persistence by rendering infected B cells refractory to
signals that can induce full VSV replication.
Results
VSV persists in mice receiving infected resting B lymphocytes
It has been demonstrated in this laboratory that VSV persistently infects resting
primary B cells from bcl-2 transgenic mice (B/bcl-2 cells), and persistence is maintained
for several weeks in culture. These infected B cells produce low levels of viral
transcripts, but no detectible proteins or infectious particles; however, virus can be
reactivated at any time by treatment of the cells with varous B cell activators (35, 36)
and (M. Schmidt , manuscript in preparation). The ability of resting B cells to maintain
the genome of an RNA virus for extended periods suggests that these cells are ideal hosts
for a persisting RNA virus in vivo; the fact that viral proteins and infectious particles are
not produced in resting B cells means that the virus should be able to evade the host
immune response. To test whether B cells can function as a reservoir for VSV in vivo
without being cleared by the immune system or eliminated by replicating virus, small
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resting B cells from xid-bcl- transgenic mice were infected with VSV, adoptively
transferred into irradiated or unirradiated xid recipients, and spleens harvested on day 10
30, or 72 after adoptive transfer for analysis. xid-bcl- transgenic B cells were used in
initial experiments to maximize the chances of maintaining persistently infected cells; the
bcl-2 transgene enhances survival (98 , 175) while the xid mutation renders the cells less
sensitive to environmental signals in vivo (Chapter II). xid recipients were used because
the number of mature peripheral B cells in these mice is reduced (117 , 176); this allows
for the adoptive transfer of cells without irradiation , which could alter the in vivo
cytokine environment and thus the activation state of the transferred cells. Iradiation
could, however , increase the efficiency of uptake of the transferred cells , so both
irradiated and unirradiated recipients were used. xid mice make normal antibody
responses to VSV (177), so persistence could be studied in the context of a normal
Immune response.
A persistent virus infection was defined as the ability to detect viral RNA by RT-
PCR but not infectious paricles in a paricular tissue, whereas in a productive infection
viral RNA and infectious paricles should be detected. The RT-PCR assay could detect
one VSV infected B cell in the presence of 10 uninfected B cells (data not shown). VSV
persisted in the spleens of both irradiated (data not shown) and unirradiated xid mice
receiving infected B lymphocytes for at least 72 days (Figure 9, Table 1). Similar results
were obtained using normal bcl-2 transgenic or non-transgenic B cells as donors
demonstrating that VSV persistence was not unique to xid or bcl-2 transgenic B cells
(Figure 11 and data not shown). Irradiation of recipients did not increase the frequency
with which viral RNA was detected, indicating that there was sufficient space in
unirradiated xid recipients to allow for survival of the adoptively transferred B cells (data
not shown). These data were consistent with the idea that VSV RNA was maintained in
B cells after adoptive transfer, but it was possible that infectious virus was produced by
the transferred B cells and maintained in host cells other than B lymphocytes. This
possibilty was addressed by experiments described below.
VSV persistence was also observed in the brains of some unirradiated infected B
cell recipients (Table 1). This is interesting because VSV usually replicates very
efficiently upon entering the CNS and causes hind-limb paralysis and death within 7-
days (178); thus , it seems unlikely that viral RNA was maintained in cells of the CNS.
While hind-limb paralysis and death were seen in some irradiated recipients of infected B
cells , there were irradiated recipients in which viral RNA was detected in the absence of
infectious virus (data not shown). One possibility was that persistently infected B cells
may have crossed the blood-brain barrier and may acted as reservoirs for virus in the
brain. This would not be unprecedented, since it has been suggested that B cells cary
other infectious agents (JC virus or prion proteins) across the blood-brain barer and into
the CNS (179 , 180). Future experiments wil determne if, in fact, VSV is maintained in
B cells in the CNS. If true , this would provide a model in which to study the mechanisms
by which persistence is maintained in the CNS and the long-term consequences of such
an infection to the host.
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Figure 9. VSV RNA persists in the spleens of infected B cell
recipients. Small resting splenic B cells purified from
CBAI-bcl-2 transgenic mice (xid) were infected with VSV-
SLC at moi=lO, extensively washed and 20x10 cells
injected into unirradiated CBAI (xid ) recipients via the
lateral tail vein. On day 10 after transfer, the indicated tissues
were removed RNA extracted, and nested RT-PCR was
performed as described in Materials and Methods; random
primers were used for the RT reactions and primers for VSV
M or actin for the PCR reactions. PCR products were run on a
2% agarose gel and detected by ethidium bromide staining.
Lanes 1 , 7 , 10 blood; Lanes 2 , 5 , 8 , 11 spleen; Lanes 3 , 6 , 9
12 brain; Lane 13 molecular weight markers; Lane 14 infected
B cell RNA (positive control); Lane 15 uninfected B cell RNA
(negative control).
Organ
Spleen Brain
Day Viral Infectious Viral Infectious
Post RNA virus RNA virus
Transfer detected isolated detected isolated
10/13 0/13 1/13 (8%) 0/13
(77%)
7/9 0/5 2/5 (40%) 0/5
(78%)
1/4 1/4 (25%)
(25%)
Table 1. VSV persistence in the spleen and brain of infected B cell
recipients. Small resting splenic B cells from xid-bcl- transgenic mice
were infected at moi=lO with VSV -SLC and injected via the lateral tail
vein into unirradiated xid recipients. Spleens and brains were harvested
from recipients on the indicated day after transfer and assayed for the
presence of viral RNA by RT-PCR or infectious virus by plaque assay.
D. not determined.
VSV persists in adoptively transferred B lymphocytes
While these results were consistent with the idea that VSV RNA was maintained
in resting B cells in vivo, it was possible that the donor cells produced virus upon transfer
which was then maintained in another cell type in the spleen of B cell recipients. 
examine this possibility, small resting splenic B cells were labeled with the vital
fluorescent dye CFSE before infection and adoptive transfer into xid recipients. CFSE
allows one to tracK adoptively transferred cells as well as determne their cell division
history (101), and the dye does not inhibit production of virus from infected B cells
stimulated in vitro (laboratory observations). Infected , CFSE+ bc1-2 transgenic or non-
transgenic B cells could clearly be seen in recipient spleens two weeks after adoptive
transfer, indicating that virus replication did not eliminate infected cells after transfer; the
lower intensity CFSE+ peaks demonstrated that a fraction of the transferred B cells had
divided, indicating homeostatic proliferation (Figure 10). The fact that some infected B
cells divided in xid recipients suggested that these cells respond to homeostatic signals in
the same way as uninfected B cells (Chapter III). To determne if virus remained in
adoptively transferred B cells, CFSE+ and CFSE' cells were purified from recipient
spleens by FACS sorting. RNA was extracted from each population of cells and
subjected to RT-PCR; the results clearly showed that VSV RNA was maintained in
adoptively transferred B cells (Figure 11 , lanes 5 and 6). Whether viral RNA was
maintained only in non-dividing cells was not determned because both dividing and non-
dividing cells were included in the sort gate. Given the fact that proliferation of VSV
infected B cells in vitro is associated with the production of infectious virus (36),
however, it is reasonable to hypothesize that some level of virus expression is induced in
proliferating B cells in vivo. Consistent with this , VSV RNA was detected by RT-PCR in
recipient (CFSE') cells in some experiments , suggesting that virus produced by donor
cells was transferred to cells in the host (Table 2). It was also possible , however, that
some infected B cells divided to the extent that CFSE staining was lost; thus, some
infected donor B cells might be present in the CFSE- population. Experiments designed
to demonstrate the induction of virus expression more directly are described below.
Overall , these data are consistent with the idea that VSV can persist in B cells in vivo in a
quiescent state.
10000
Bcl-2 transgenic B cells Non-transgenic B cells
10000
100
, .., '
1000 10000100100 1000
CFSE
Figure 10. VSV infected B cells survive and proliferate after adoptive transfer
into xid recipients. Small resting splenic B cells purified from CBAlCa or
CBAlCa-bcl- transgenic (normal) mice were stained with 1 /-M CFSE
infected with VSV -SLC at moi=lO , and 20x10 cells injected into unirradiated
CBA/ (xid) recipients via the lateral tail vein. On day 14 after transfer, spleen
cell suspensions were made from the recipients as described in Materials and
Methods, stained with anti-B220-APC , and analyzed by flow cytometry.
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Figure 11. VSV RNA persists in adoptively transferred
cells. Small resting splenic B cells purified from
CBAlCa-bcl-2 transgenic (normal) mice were stained
with 1 I-M CFSE, infected with VSV-SLC at moi=lO
and 20x10 cells injected into unirradiated CBA/ (xid)
recipients via the lateral tail vein. On day 14 after
transfer, spleen cells from 2-3 recipients were pooled
and FACS sorted to obtain CFSE+ (donor) and CFSE-
(recipient) populations. RNA was extracted from each
cell population and subjected to nested RT-PCR to
amplify VSV M or actin sequences as described in
Materials and Methods and in the legend for Figure 2.
PCR products were run on a 2% agarose gel and
detected by ethidium bromide staining. Lanes 1: input
infected B cells , 2: uninfected B cells, 3: total spleen
infected B cell recipients , 4: total spleen , uninfected B
cell recipients , 5: CFSE+ cells , infected cell recipients
6: CFSE- cells, infected cell recipients, 7: positive
control RNA , 8: negative control RNA.
Input Cells Total Spleen CFSE (+) CFSE (-)
Experiment 1
RT-PCR 1
RT-PCR 2
Experiment 2
RT-PCR 1
RT-PCR 2
Experiment 3
RT-PCR 1
RT -PCR 2
RT-PCR 3
Total: 7/7
(100% )
6/7
(86% )
6/7
(86% )
3/7
(43%)
Table 2. VSV persists in adoptively transferred B cells. Summary of
three independent experiments performed as described in Figure 3. RT-
PCR was repeated two to three times on each sample; + indicates VSV
M sequences were detected, - indicates no PCR product.
Recipients of infected B cells make an antibody response to VSV
The hypothesis that virus expression was induced in B cells undergoing
homeostatic proliferation predicts that an immune response to VSV should be generated
in the recipients. This proved to be the case because unilTadiated xid recipients of VSV
infected B cells made anti VSV IgM and IgG responses that were similar to those in xid
mice that had received 10 PFU of VSV Lv., suggesting that infectious virus or viral
proteins were produced by donor cells (Figure 12A). There were two possible
explanations for this; (1) non-internalized virus was carred in on the surface of donor
cells , or (2) a fraction of donor cells was activated to produce viral antigens in vivo after
transfer. When infected B cells were treated with mouse anti-VSV serum to neutralize
any non-internalized virus prior to transfer, recipient mice stil made IgM and IgG
responses to VSV that were comparable to recipients of untreated infected cells (Figure
12B). This suggests that antibody was made in response to viral antigens produced by
infected B cells, not to virus cared in on the surface of the cells. While there are a small
number of virus producing cells before transfer (1-2 infectious centers per 10 cells with
anti- VSV treatment), the robust nature of the antibody response suggests that some
resting, non-virus producing B cells were activated to produce virus or viral proteins
upon adoptive transfer. Given the fact that a fraction of infected B cells divided after
adoptive transfer into xid recipients (Figure 10), one possible source of inductive
signaling that would lead to VSV activation is homeostatic proliferation.
Figure 12A. Antibody response to VSV in infected B cell recipients
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Figure 12B. Pre-treatment of infected cells with anti- VSV serum
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Figure 12. Antibody response to VSV in infected B cell recipients. A. Unirradiated
CBAIN (xid) mice were injected via the lateral tail vein with either 10 PFU of VSV or
20x10 small , resting, VSV-SLC infected splenic B cells from CBA/Ca (normal) mice.
Levels of VSV specific IgM and IgG were assessed on day 4 , 7 , and 14 in individual
mice by ELISA. Each bar represents the mean ELISA titer of three mice. B. Infected B
cells were either treated with mouse anti-VSV serum (+ Ab) or not (no Ab) before
adoptive transfer into unirradiated xid recipients. Levels of VSV specific IgM and IgG
were assessed on Day 0 , 4 , 7, and 12 by ELISA as described above; each bar represents
the mean ELISA titer of three mice.
Infectious VSV cannot be recovered from the spleens of infected B cell recipients
Demonstrating maintenance of VSV RNA in adoptively transferred B cells was
the first step in developing an in vivo model in which to study RNA virus persistence in
lymphocytes. An important feature of viral persistence is the ability of virus to
periodically reactivate, produce infectious virus , and potentially cause overt disease in the
host. This is important in the pathogenesis of persistent viral diseases as well as in the
maintenance of virus in a population of potential hosts. In initial experiments , VSV RNA
was detected by RT-PCR in the spleens of infected B cell recipients , but infectious virus
was not detected by plaque assay. Attempts to activate persistently infected B cells using
B cell activators that enhance VSV replication in the in vitro system were also
unsuccessful. Since in vitro experiments demonstrated that infectious virs could be
reactivated from resting B/bcl-2 cells after weeks in culture (M. Schmidt, manuscript in
preparation), this suggests that persistence in vivo was maintained by factors not present
in vitro.
One of the differences between the in vitro and in vivo systems was the presence
of interferon in vivo. VSV is sensitive to type I (a j3 and type II (y) interferons, which
restrict virus replication at multiple levels and are important for control of VSV infection
in mice (28 , 95). Thus, it was possible that infected B cells were exposed to interferons
after adoptive transfer which restricted the reactivation of virus from these cells while
allowing viral RNA to persist. This idea was tested by using IF a/j3 receptor knock-out
mice as B cell donors; thus , the infected, adoptively transferred B cells were
unresponsive to type I interferons. Attempts to reactivate VSV in vitro from infected IFN
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B cells which had been maintained for 7- 14 days in. wild-type mice were also
unsuccessful, despite the fact that adoptively transferred cells could be seen (by CFSE
staining) and that viral RNA could be detected in the spleens of recipients by RT-PCR.
In other experiments , infected IFN a/ B cells were maintained in wild-type
recipients, then total spleen cells from these primary recipients were transferred into 
secondary recipients in which 30-50 PFU of VSV is 100% lethal (95); these
recipients survived, further suggesting that VSV reactivation was not suppressed by Type
I interferons. One possibilty is that IFN y suppressed reactivation; the fact that 
mice are highly susceptible to VSV argues against this since IFN y does not
inhibit virus replication in these mice (95). It is also possible that IF y is a stronger
inhibitor of virus replication in B cells than in other cell types. This, however, seems
unlikely because treatment of infected B cells in vitro with 60 U/ml of IFN y does not
completely suppress virus replication (laboratory observations). These data indicate that
VSV reactivation from adoptively transferred B cells is blocked by an interferon
independent mechanism. The finding that VSV persistence was maintained in the
presence of an antibody response to the virus (Figure 12A and B) could suggest that
antiviral antibodies playa role in restrcting VSV reactivation from B cells.
Reactivation of VSV from persistently infected B cells in vito is inhibited by
prolonged treatment with anti- VSV serum
Restriction of virus replication by antiviral antibodies is another mechanism by
which viral persistence might be maintained in vitro and in vivo. This mechanism has
been reported for RNA viruses such as measles virus, rubella virus, and Sindbis virus (77,
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, 87). This phenomenon has been well-studied in cells of neural origin (80 , 83 , 86,
181), but there is limited information regarding its importance in cells of the immune
system (81 87). In these systems , when infected cells or infected animals are treated
with antibodies to viral proteins , viral mRA, protein and infectious paricle production
are suppressed (77, 80-83, , 87). Furthermore , the effect is reversible since removal of
antibody results in the re-expression of viral mRNAs, proteins and infectious particles
(80 , 83 , 87). In vivo, antibodies are thought to exert their antiviral activity in the
following ways: neutralization of extracellular virus , killng of infected cells by antibody-
dependent cell-mediated cytotoxicity (ADCC), or destruction of infected cells by
complement mediated lysis (67). These data suggest, however, that antiviral antibody
can also act directly on infected cells by restricting virus replication without killing the
cells. Any mechanism of non-cytolytic control of virus replication may be involved in
the maintenance of virus persistence.
The fact that VSV was maintained in B cells in the presence of an antibody
response to the virus led me to hypothesize that antiviral antibodies were suppressing
virus reactivation from infected B cells. To test this idea directly in the absence of other
immune effectors such as virus specific T cells, NK cells , or complement, I took
advantage of the fact that VSV persistence can be maintained for weeks in cultures of
primary B/bcl-2 cells (M. Schmidt, manuscript in preparation). In this way, infected B
cells could be treated with antiviral antibody for extended periods and the effects of this
treatment on virus reactivation observed. Small resting splenic B/bcl-2 cells were
prepared, infected with VSV, and cultured for two to seven days with normal mouse
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serum (NMS) or anti-VSV serum at a 1:500 or 1:1000 dilution; these dilutions were used
to maximize the amount of antiviral antibody present while minimizing any nonspecific
effects of other serum proteins. Following this treatment, antiviral antibody was washed
out and virus production was assessed by plaque assay after stimulation of the cultured
cells with the B cell specific activators anti-Ig+IL-
Short-term treatment with anti- VSV serum (2 days) hadno effect on virus
reactivation since the levels of infectious virus produced were similar to those seen in
acutely infected cells are infected cells treated with NMS for 2 days (Figure 13A). This
demonstrated that antibody treatment did not block virus uptake. In contrast , anti- VSV
treatment for 7 days resulted in complete inhibition of virus reactivation; less than 1 PFU
per 10 B cells versus 5800 PFU per 10 B cells for NMS treated controls (Figure 13A
Table 3). This showed that prolonged exposure of infected cells to antiviral antibody was
required to mediate inhibition , suggesting a diect effect of antibody on viral replication
within the cells. General inhibition of B cell activation was an unlikely explanation for
the lack of virus replication since the persistently infected B cells treated with anti- VSV
serum proliferated as well as uninfected cells in response to all activators tested (Figure
13B and data not shown). Persistently infected B cells treated with NMS or acutely
infected B cells , on the other hand, showed greatly reduced proliferation after activation;
this is likely due to killng of activated cells by the virus.
The maintenance of VSV persistence in BHK cells requires that the virus spreads
at a low level from cell to cell; thus treatment with anti-VSV antibody, which inhibits this
spread, leads to elimination (or "curing ) of virus from the cells (22). Experiments in this
, .
/i-r .
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laboratory show that very litte cell to cell spread of VSV occurs in long-term cultures of
persistently infected resting primary B cells , suggesting that persistence in B cells does
not depend on this mechanism (M. Schmidt, laboratory observations). Consistent with
this , treatment with anti- VSV serum did not cure the B cells of virus , since in many cases
virus could be reactivated from antibody treated cells that had been recultured for 1-
weeks in the absence of antibody (Figure 13C , Table 4). Overall , these data are
consistent with the idea that antibodies to VSV proteins directly inhibit reactivation of
virus from persistently infected B cells in a reversible fashion, demonstrating the
potential of components of the specific immune response to maintain virus persistence in
lymphocytes.
Figure 13A. Inhibition of VSV reactivation from B cells by VSV immune serum
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Figure 13B. Proliferation of Persistently Infected B Cells Treated With VSV Immune Serum
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Figure 13. Inhibition of VSV reactivation from B cells by VSV immune serum. A. 
Small , resting splenic B cells from CBNCa-bcl-2 transgenic mice were prepared on
Percoll step gradients. VSV -SLC infected or uninfected B cells were cultured in the
presence of a 1 :500 dilution of normal mouse serum (infected cells) or mouse anti-VSV
serum (infected and uninfected cells) for 2 or 7 days. On the indicated days , cells were
harvested, washed extensively, and uninfected cells were acutely infected with VSV-
SLC. Each cell population was then cultured in media alone (un stimulated) or in the
presence of anti-Ig+IL-4 as described in Materials and Methods. Virus titers (PFU per
cultured B cells) were determned after 48h of activation by plating serial dilutions of
culture supernatants on CHO monolayers. B. Proliferation of uninfected B cells and
VSV infected B cells treated with NMS or anti-VSV serum for 7 d was assessed by
H)TdR incorporation in 8 h pulses at 42 to 48 h after activation. Cells were cultured in
media alone (unstimulated) or stimulated with anti-Ig+IL-4. C. VSV infected B cells
were treated with NMS or anti- VSV serum for 7 days, activated with anti-Ig+IL-4 for
48h after extensive washing, and virus titers measured in culture supernatants. The
remaining cells were placed in culture in the absence of NMS or anti- VSV serum for an
additional 7 days. After this second culture period, the cells were again harvested,
activated with anti-Ig+IL-4, and virus titers determned.
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FreQuencv of virus inhibition
Concentration
Antibody Dilution 10 f.glml 1 f.glml
NMS 0/9
anti- VSV serum 9/10 (90%)
Control ascites 0/4
1E9 ascites (neutralizing) 5/6 (83%)
8E 11 ascites 2/4 (50%)
(non - neutralizing)
NMS IgG 0/3
anti-VSV IgG 3/3 (100%) 2/3 (67%)
anti-VSV IgG F(ab' 3/3 (100%) 2/3 (67%)
anti-VSV IgG Fab 4/4 (100%) 0/4
Table 3. Summary of virus inhibition experiments. The frequency
of inhibition for each antibody was determned by dividing the
number of experiments in which the antibody inhibited infectious
virus production by the total number of experiments. Inhibition
was defined as at least a lO-fold reduction in virus titer compared
to NMS or control ascites after activation with anti-Ig+IL-4 for
48h. Monoclonal antibodies: 1E9 (neutralizing anti-VSVG, IND);
8E11 (non-neutralizing anti-VSVG, IND). * NMS and anti-VSV
serum were used at 1:500- 1:1000 , ascites fluids at 1:100-1:500.
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VSV reactivation from persistently infected B cells is inhibited by intact IgG, F(ab'
and Fab fragments purifed from anti- VSV serum
While the data presented above suggested that anti- VSV antibody in the immune
serum was directly suppressing virus reactivation , it was possible that other serum
components were involved. For example, interferons are induced by virus infections and
inhibit virus replication while complement forms complexes with antiviral antibodies to
lyse infected cells (28 , 67). In order to directly demonstrate that inhibition of VSV
reactivation was mediated by antibodies and not other components of immune serum
IgG was purified from the normal mouse serum or VSV immune serum used in previous
experiments (NMS IgG or anti- VSV IgG). VSV infected B/bcl-2 cells were treated NMS
IgG or anti-VSV IgG for 7 days; thereafter, the cells were washed to remove antibody
and virus reactivation was assessed after stimulation of the cells with anti-Ig+IL-4 and
titering culture supernatants on CHO cells. Intact anti- VSV IgG inhibited virus
reactivation at 1 and 10 I-g/ml , but not at 0. 1 I-g/ml while NMS IgG did not inhibit at any
concentration (Figure 14A , Table 3 and data not shown). While this demonstrated that
antibodies in VSV immune serum were responsible for inhibition, the mechanism
underlying this effect was not determned.
Cross-linking of Fcy receptor inhibits anti-immunoglobulin induced B cell
activation at several levels including blastogenesis , proliferation c-myc mRNA induction
and antibody secretion (182- 184). Thus, it was possible that simultaneous binding of
VSV G and Fc receptors on the cell surface by antiviral antibodies mediated inhibition of
B cell activation when the cells were treated with anti-Ig+IL-4. One argument against
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this hypothesis was that IL-4 overcomes Fc-mediated inhibition of B cell activation (185,
186). Another was that infected B cells treated with anti- VSV antibody proliferated in
response to all B cell activators tested (Figure 13B and data not shown). To directly look
at the involvement of Fc mediated effects in VSV inhibition , F(ab' )2 fragments prepared
from the anti- VSV IgG , which are bivalent antibodies lacking the Fc portion, were used
to treat infected B cells for seven days , and virus reactivation was determned as
described above. This preparation inhibited virus reactivation as efficiently as intact IgG
providing further evidence that Fc signaling was not required for this process (Figure
14A and Table 3).
A second mechanism by which antiviral antibodies might inhibit virus
reactivation is through generation of an intracellular signal as a consequence of cross-
linking viral proteins on the surface of infected cells , resulting in the inhibition of cellular
pathways required to support virus replication. This could occur through direct signaling
by viral proteins or indirect signaling through cellular proteins associated with viral
proteins. It has been shown that treatment of measles virus infected cells with anti-
measles antibodies triggers the breakdown of phosphoinositide, a component of
numerous signaling pathways (187), suggesting that viral proteins can be coupled to
cellular signaling pathways. To determine if cross-linking viral proteins was required for
the inhibition observed in VSV infected B lymphocytes , persistently infected B cells
were treated for seven days with intact, F(ab' )2' or Fab fragments of anti-VSV IgG or
with intact NMS IgG; virus reactivation was then assessed as described above. Although
anti- VSV Fab fragments inhibited virus reactivation , they were less efficient than intact
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- IgG or F(ab' )2 fragments since inhibiton was only seen at 10 Ilg/ml, whereas intact or
F(ab' )2 fragments worked at a ten-fold lower concentration (Figure14A). This inhibition
occurred despite the fact that aggregates in the Fab preparation , which could cross-link
viral proteins, were removed by high speed centrifugation. The fact that Fab fragments
inhibit virus reactivation less efficiently than bivalent antibodies suggests the following:
generation of a putative inhibitory signal occurs at some level with monovalent
antibodies at high concentration , but signaling is optimal when viral proteins are cross-
linked. This may be due to stabilzation of antibody-protein interactions by cross-linking.
Overall , these data demonstrated 1) that antibody in VSV immune serum mediated
inhibition of virus reactivation; 2) that Fc mediated inhibition of B cell activation was not
involved in virus suppression; 3) that cross-linking of viral proteins was not essential , but
made virus inhibition more efficient.
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Figure 14A. Inhibition of VSV reactivation by F(ab' h and Fab fragments of anti- VSV
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Figure 14. Inhibition of VSV reactivation from persistently infected B cells by anti- VSV
F(ab' )2' Fab fragments, and monoclonal antibodies. A. VSV infected bcl-2 tg B cells
were cultured in the presence of purified IgG from NMS, anti-VSV serum, or anti-VSV
F(ab' )2 or Fab fragments for 7 d at the indicated concentrations. The cells were then
harvested, washed extensively, activated with anti-Ig+IL-4 for 48 h, and virus titers
measured: B. The experiment was performed essentially as described in 6A. VSV
infected B cells were treated with control ascites or ascites containing the following
monoclonal antibodies at the indicated dilutions: 1E9 (neutralizing, IN specific);
5E4D8 (non-neutralizing, IN/NJ cross-reaCtive); 8E11F2 (non-neutralizing, INn
specific); 10G4 (anti-VSV N).
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Inhibition of VSV reactivation from persistently infected B cells by neutralizing and
non-neutralizing monoclonal antibodies
Since anti- VSV serum contained antibodies specific for all viral proteins , it was
possible that interactions between antibody and one or more viral proteins were required
to inhibit VSV reactivation. It has been shown , however, that treatment of cells infected
with measles virus (HeLa cells, C6 rat glioma cells) or Sindbis virus (rat dorsal root
ganglion neurons) with monoclonal antibodies to viral glycoproteins inhibits viral protein
and infectious paricle production; in the case of measles virus, neutralizing activity was
required for this effect (79, 80, 181). These studies suggest that antibody binding to viral
glycoproteins on the cell surface is sufficient to inhibit virus replication.
To determine if a similar mechanism operated in persistently infected primary B
cells , these cells were treated with monoclonal antibodies specific for VSV G, the viral
glycoprotein , or VSV N, the nucleocapsid protein which is associated with viral genomic
RNA (17). A neutralizing monoclonal antibody specific for VSV G-Indiana (lE9)
inhibited virus reactivation in most experiments while an antibody specific for VSV N
(lOG4) did not, suggesting that binding to VSV G was suffcient to inhibit (Figure 14B
and Table 3). It seems likely that neutralization is not required since a non-neutralizing
antibody specific for VSV G-Indiana could inhibit; a second monoclonal antibody, which
was non-neutralizing and Indiana-New Jersey cross-reactive did not inhibit virus
reactivation (Figure 14B and Table 3). This was in contrast to the requirement for
neutralizing activity in measles virus inhibition (80) but consistent with the observation
that HSV - 1 reactivation from trigeminal ganglia was inhibited by nonneutralizing
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monoclonal antibodies (86). Why do nonneutralizing antibodies inhibit less efficiently?
VSV specific neutralizing and nonneutralizing monoclonal antibodies bind distinct
epitopes (105, 106), so it was possible that antibody binding to different epitopes had
slightly different biological effects. Alternatively, it has been proposed that the main
difference between neutralizing and non-neutralizing antibodies is that neutralizing
antibodies bind envelope or capsid proteins with higher affinity, coat virions more
effectively, and block attachment or entry (188). Thus , it was also possible that the
differences in virus inhibition were related to differences in the affinity of binding
between antibody and viral protein. The idea that avidity or affinity of binding to viral
proteins was important for virus inhibition was supported by the finding that monovalent
Fab fragments inhibited virus reactivation less efficiently than bivalent intact IgG or
F(ab' )2 fragments (Figure 14A, Table 3). The binding of one non-neutralizing antibody to
VSV G can enhance the binding of a second non-neutralizing antibody (106). Thus, it
would be useful to look at the ability of pooled non-neutralizing antibodies to inhibit
virus replication. In fact, in the HSV- 1 experiments, pooled non-neutralizing antibodies
inhibited virus reactivation much more efficiently than individual antibodies (86). Taken
together, these data suggested that antibodies that recognize VSV G were sufficient to
inhibit virus reactivation from persistently infected B cells , that neutralizing activity was
not absolutely required for this effect, and that the affinity or site of binding to VSV G
was an important factor. Whether the antibody recognizes VSV G on the surface of the
infected cell or inside the cell is not known.
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Effect of anti- VSV serum or monoclonal antibody treatment on viral RNA and
protein levels in infected B cells
Treatment of measles virus infected cells (HeLa, rat C6 glioma , mouse
neuroblastoma cells) with anti-measles serum or monoclonal antibodies to HA protein
inhibits not only infectious paricle production , but also suppresses viral proteins and
mRNAs (77- , 83). This shows that antiviral antibodies can inhibit measles virus
replication at multiple levels in cell lines. The results described above demonstrated that
anti-VSV antibodies inhibited infectious virus production in primary B cells. To see if
VSV genomic RNA, mRNAs , and proteins were also suppressed by antiviral antibody
treatment, infected B cells were treated with NMS or anti-VSV serum for seven days;
thereafter, the cells were activated with anti-Ig+IL-4 for 48h, then the cells were either
labeled with S-methionine for protein analysis by immunoprecipitation or harested for
RNA analysis by Northern blot. After seven days of NMS treatment, activated B cells
synthesized viral genomic RNA , messenger RNA, viral proteins and infectious paricles
(Figures 15A and B , lane 1). With anti-VSV serum treatment, on the other hand , viral
RNA and proteins were reduced to undetectable levels as assessed by Northern blot or
immunoprecipitation of S-methionine labeled proteins (Figures 15A and B, lane 2).
Viral mRNA transcription did continue at a very low level because VSV M mRA could
be detected by RT-PCR (data not shown). This demonstrates that antibody treatment did
not "cure" persistently B cells of the virus, which is expected as virus replication can be
restored after cessation of the antibody treatment (Figure 13C).
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Experiments described above showed that a neutralizing monoclonal antibody to
VSV G (1E9) completely inhibited infectious virus production in persistently infected B
cells (Figure 14B , Table 3). It was possible that binding of antibody to VSV G only,
inhibited virus assembly or release; however, when infected B cells were treated with
1E9 for seven days, all levels of virus replication were inhibited (genomic RNA, mRA
protein , and infectious virus production , Figures 15A and B , lane 4). In contrast
treatment with control ascites or a non-neutralizing antibody specific for VSV G (5E4D8)
did not affect virus replication at any level (Figures 15A and B, lanes 3+5). In some
experiments treatment of infected B cells with another non-neutralizIng monoclonal
antibody to VSV G (8E11) inhibited infectious virus production (Figure14B , Table 3). I
have not looked at viral RNA or proteins in cells in which 8E11 inhibited infectious
parcle production, so it remains to be determined if neutralizing activity is required for
inhibition of all levels of virus replication. Thus , as with anti- VSV serum, suppression
of infectious virus production by a neutralizing anti- VSV G monoclonal antibodies was
associated with a reduction in viral genomic RNA, mRNA and protein levels. These
results are interesting because they suggest that recognition of only VSV G by antibody
results in global suppression of virus replication.
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Figure 15. Effect of anti-VSV serum or anti-VSV monoclonal antibody treatment
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Figure 15. Effect of anti- VSV serum or anti- VSV monoclonal antibody treatment on
viral RNA and protein levels. B cells from bcl- tg mice were infected with VSV -SLC
and cultured in the presence of the indicated antibodies for 7 days. Cells were then
washed extensively and treated with anti-Ig+IL-4 to induce virus replication. After 48h
of activation , cells were either pulsed with S-methionine for 4h or harvested for RNA
isolation. VSV proteins were immunoprecipitated from S-methionine pulsed cell
extracts using rabbit anti- VSV serum and run on a 10% SDS-P AGE gel. Viral genomic
and messenger RNAs were detected by Northern blotting using pooled probes for VSV
, G, and L sequences. PFU analysis: (+) indicates virus was detected (::10 000
PFUIl0 B cells); (-) indicates no virus was detected (.:0. 1 PFUIl0 B cells). A. VSV
protein and B. RNA in infected cells treated with diluted serum or monoclonal
antibodies. Lanes: 1: normal mouse serum (1:1000), 2: anti-VSV serum (1:1000), 3:
control ascites (1:200), 4: 1E9 ascites (neutralizing, 1:625), 5: 5E4D8 ascites (non-
neutralizing, 1:200), 6: lOG4 ascites (anti-VSV N , 1:500), 7: uninfectedB cells.
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Fc is not required for suppression of viral genomic RNA and mRNA
In previous experiments , anti- VSV F(ab' )2 fragments were shown to inhibit
infectious paricle production as efficiently as intact IgG from VSV immune serum
suggesting that the Fc portion of antibody was not required for infectious virus
suppression (Figure 14A and Table 3). It was possible , however, that an Fc-mediated
signal was required for suppression of viral genomic RNA, mRA, or protein. This idea
was tested by treating VSV infected B cells with NMS IgG , anti-VSV IgG or anti-VSV
F(ab' )2 fragments as described above. At 10 Ilg/ml , both intact anti- VSV IgG and anti-
VSV F(ab' )2 fragments suppressed viral mRNAs and proteins to below the level of
detection (Figures 16A and 16B , lane 2 vs. lane 5). The suppression of mRA was seen
even after overexposure of the Northern blot; interestingly, viral genome was stil
detectable in both cell populations (Figure 16B , lane 2 ' vs. lane 5 ). The maintenance of
viral genome in these cells is consistent with the idea that treatment of infected B cells
with antiviral antibody does not "cure" the cells of virus. In other experiments , antibody-
treated cells which had no detectible viral mRNA by Northern blot analysis had low
levels of VSV M mRA that was detectible by RT-PCR (data not shown). Thus , viral
genome and low levels of mRA were likely maintained in cells treated with anti-VSV
IgG or anti-VSV F(ab' )2 fragments at 10 Ilg/ml.
In this paricular experiment, intact anti-VSV IgG at 1 Ilg/ml did not suppress
viral RNA , protein, or infectious particle production (Figures 16A and B , lane 3).
However, inhibition of infectious virus production was seen at this concentration in 2 out
of 3 experiments, indicating that suppression by this antibody preparation could occur at
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glml but was less efficient (Figure 14A a!ld Table 3). A similar efficiency of
inhibition was seen with anti- VSV F(ab' )2 fragments at 1 g/ml (2 out of 3 experiments),
suggesting that intact antibody and F(ab')2 fragments inhibit infectious virus production
by the same mechanism. Thus, any suppression of viral RNA or protein levels seen with
g/ml of anti- VSV F(ab' )2 would probably also be seen with intact antibody under
conditions where infectious particle production was inhibited. Treatment of infected B
cells with 1 g/ml of anti- VSV F(ab' )2 fragments had little effect on viral protein levels
(except for a slight decrease in M protein), but reduced viral RNA levels (genome and
message) and inhibited infectious virus production completely relative to NMS IgG
treatment (Figures 16A and B , lane 4- F(ab' )2 vs. lane 1-NMS IgG). This suggests that Fc
is not required to suppress viral RNA levels; to determne if Fc signaling is required for
inhibition of protein synthesis , an experiment wil have to be performed in which both
intact anti-VSV IgG and F(ab' )2 fragments inhibit infectious virus production at 1 g/ml.
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Figure 16. Effect of anti-VSV IgG , anti-VSV F(ab' )z, or anti-VSV Fab fragments
on viral RNA and protein levels
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Figure 16. :ffect of anti- VSV IgG, anti- VSV F(ab' )2' or anti- VSV Fab fragments on viral
RNA and protein. The experiment was performed as described in Figure 13. PFU
analysis: (+) indicates virus was detected (:;10 000 PFU/10 B cells); (-) indicates no
virus was detected (.:0. 1 PFUIl0 B cells). A. VSV protein and B. RNA in infected
cells treated with IgG purified from NMS or anti- VSV serum. Lanes: 1: normal mouse
serum IgG (10 J.g/ml), 2: anti- VSV IgG (10 J.g/ml), 3: anti- VSV IgG (1 J.g/ml), 4: anti-
VSV F(ab' )2 (1 J.glml), 5: anti- VSV F(ab' )2 (10 J.g/ml), 6: anti- VSV Fab (10 J.g/ml), 7:
anti-VSV Fab (1 J.g/ml). * Longer exposure of lanes 2 and 4-
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Does signal strength determine the level at which VSV replication is inhibited in
anti- VSV treated B cells?
There are two possible mechanisms by which antiviral antibodies could inhibit all
levels of virus replication in B cells. First, antibodies might enter cells , interact with their
target proteins and directly inhibit their function in virus replication. This possibility is
minimized by the finding that a monoclonal antibody to VSV G inhibits all levels of virus
replication in B cells (Figure 15A and B , lane 4). Since VSV G is only involved in
attachment to cells , assembly, and release of virus from cells (17), it is difficult to
envision how antibody binding to this protein would suppress viral RNA and protein
levels. This leads to the hypothesis that interactions between VSV G and antibody
generate intracellular signal(s) that specifically inhibit cellular pathways required to
induce VSV replication in B cells. VSV replication is regulated at multiple levels in
primary B cells , and different cellular signaling pathways likely regulate each stage of
virus replication (36). By analogy with antigen receptors , in which the strength of signal
has different functional consequences (189), one might predict that the level at which
virus replication is inhibited depends on the strength of the putative inhibitory signal(s)
generated by antiviral antibodies. The strength of signaling generated by antibodies to
cellular receptors depends on the concentration of antibody and its abilty to cross-link;
high concentrations of antibody and bivalent binding generate stronger signals (189).
Consistent with the idea that signal strength is important in the suppression of VSV
replication , the ability of anti- VSV antibodies to cross-link viral proteins was important
for efficient inhibition of infectious paricle production (Figure 14A and Table 3). Cross-
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linking may enhance the stability of antibody-viral protein interactions leading to a
stronger signal.
Cross-linking was also required for efficient suppression of viral RNA and protein
levels. At 10 jlg/ml , anti- VSV Fab fragments inhibited infectious paricle production;
while this treatment also reduced genomic and mRA levels relative to NMS IgG
treatment (Figure 16B lane 6 vs. lane 1), mRA levels were higher compared to
treatment with intact anti-VSV IgG or F(ab' )2 fragments at the same concentration
(Figure 16B , lane 6* vs. lanes 2* and 5*) Thus, a further reduction in mRNA levels
required a stronger "signal'; induced by cross-linking. Consistent with this idea, viral
genomic and mRA levels are much lower in cells treated with 10 jlg/ml of anti-VSV
F(ab' )2 compared to 1jlg/ml (Figure 16B , lane 4 vs. lane 5). This suggests that a stronger
inhibitory signal is delivered by F(ab' )2 fragments at higher concentration. In contrast to
genomic and mRA levels, viral protein levels were essentially unaffected by treatment
with 10 jlg/ml of anti- VSV Fab compared to intact anti- VSV and F(ab' )2 fragments used
at the same concentration (Figure 16A , lane 6 vs. lanes 2 and 5). The only exception was
a slight decrease in VSV M protein , which was also seen with anti-VSV F(ab' )2 at
1 jlg/ml , suggesting that M protein may have been selectively destabilized under some
conditions of antibody treatment (Figure 16A , compare lanes 4 and 6 to lane 1). These
data suggested that suppression of viral protein levels required a very strong inhibitory
signal (high concentrations of bivalent antibody).
Overall the results with intact anti- VSV IgG , F(ab' )2' and Fab fragments are
consistent with the idea that the strength of the putative inhibitory signal(s) generated by
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antiviral antibody treatment differentially inhibits virus replication in infected B cells.
The data summarzed in Table 4 suggest the following: 1) Fc is not required for inhibition
of viral RNA (genomic or message); 3) inhibition of infectious virus production requires
a weak inhibitory signal; 4) suppression of viral genomic or mRNA is more dependent on
signal strength; 5) suppression of viral protein levels (except VSV M) requires a very
strong signal. Thus , antiviral antibody inhibits VSV replication at multiple levels in B
cells and the extent of inhibition may depend on the strength of inhibitory signal(s)
induced by the antibody.
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Inhibitory signal: Strong Weak None
1 0 g/ml g/ml 1 0 g/ml g/ml
bivalent bivalent monovalent monovalent
PFU
++++ ++++ ++++
mRA
+++
Genome
+++
Protein
Table 4. Inhibition of VSV replication at multiple levels in
anti-VSV treated B cells. Summary of the data presented in
Figures 14A and 14B demonstrating the extent to which the
indicated antibody preparations inhibited each stage of virus
replication. The degree of inhibition ranged from complete
(++++) 
to none (-). The putative inhibitory signal(s) generated
by antiviral antibodies were classified as strong (high
concentrations of bivalent antibody), weak (low concentrations
of bivalent antibody or high concentrations of monovalent
antibody), or none (low concentrations of monovalent
antibody).
- j
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Reactivation of infectious virus after recovery from antibody treatment
A hallmark of persistent infection is the ability of infected cells to periodically
produce infectious virus. In vivo studies described earlier in this chapter demonstrated
that VSV persistence was maintained in B cells in a type I interferon independent manner
in the presence of high levels of anti VSV antibody. It is proposed here that suppression
of virus reactivation from persistently infected B cells by antiviral antibody is a
mechanism for maintaining VSV persistence in B cells. In order to demonstrate that
antiviral antibodies maintained persistence and did not clear virus from infected B cells,
the following experiment was performed: persistently infected B cells were treated with
antiviral antibodies for 7 days; the cells were then washed extensively and re-cultured for
14 days in the absence of antibody. After this culture period, the cells were stimulated
with anti-Ig+IL-4 for 48h and virus titers in culture supernatants determned. TreatIllent
of infected B cells with anti- VSV serum for 7 days resulted in complete inhibition of
infectious virus production which was reversed after reculturing the cells without anti-
VSV serum for 7 days (Figure 13C). Recovery of virus from anti-VSV serum treated
cells was not a consistent finding (4 of 6 experiments, Table 5). Virus could not be
recovered from B cells treated with purified anti- VSV IgG, and only rarely from anti-
VSV F(ab' )2 treated cells (0 of 4 and 1 of 5 experiments respectively, Table 5).
Importantly, viral genome is stil present in anti-VSV IgG or anti-VSV F(ab' )2 treated B
cells even when infectious virus is suppressed , demonstrating that virus is not completely
cleared from the cells (Figure 16B lanes 2 , 4 , and 5 ). Cultures in which infectious
virus production was initially inhibited by anti-VSV Fab fragments (10 J.g/ml), on the
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other h,:md, could always be activated to produce infectious virus 7- 14 days after antibody
removal (3 of 3 experiments , Table 5). Since Fab fragments inhibited virus reactivation
less efficiently than intact IgG or F(ab' )2 fragments (Figure 14A , Table 3), this suggested
that the initial " strength" of inhibition determined whether virus could be recovered from
antibody treated cells. It was possible that a strong inhibitory signal required a longer
recovery period following antibody removal. Overall , these data demonstrate that
inhibition of virus replication by antiviral antibody is reversible , providing a mechanism
by which VSV could be reactivated from persistently infected B cells in vivo.
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Antibody
anti- VSV serum
Recovery of virus after treatment
4/6 (67%)
0/4
1/5 (20%)
3/3 (100%)
anti-VSV IgG
anti- VSV F(ab'
anti-VSV Fab
Table 5. Summary: Reactivation of virus after recovery from
antibody treatment. Small , resting bcl-2 transgenic B cells
were infected with VSV-SLC and treated for one week with
the indicated antibody. Cultures in which virus production
was suppressed were washed to remove antibody and then re-
cultured for one to two weeks in the absence of antibody.
Percentages reflect the number of experiments in which virus
could be reactivated after recovery from antibody treatment
out of the total number of experiments.
J..
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Inhibition of transcription from HA VSV in B cells by anti-VSV IgG
In resting B cells infected with VSV, viral protein synthesis is undetectable by
immunoprecipitation of S-methionine labeled cell extracts with polyclonal rabbit anti-
VSV serum (36). This leads to the following question: if treatment of persistently
infected, resting B cells with antibody recognizing VSV G inhibits virus reactivation
where does the VSV G protein come from? It was possible that a very low level of viral
proteins were continuously made in these cells; alternatively, VSV G from input virions
may remain on the cell surface, possibly associated with host cell proteins. In order to
determne if de novo synthesis of VSV G was required for antibody inhibition , an
experiment was performed using a virus (ilG-HA VSV) generously provided by Dr. Jack
Rose. In this virus , the gene encoding VSV G has been deleted and replaced with
sequences encoding influenza HA (99). This virus was grown in a VSV G expressing
cell line so that infectious virions containing G protein were produced , but once this virus
enters cells , it can only produce influenza HA and not VSV G; thus , any VSV G found in
infected cells is derived from input virions. Small resting splenic B cells were infected
with a low-titer stock of ilG-HA VSV at moi=O. l and treated with either NMS IgG or
anti-VSV IgG for seven days , and the cells activated with anti-Ig+IL-4 for 48h before
analysis. The use of a low multiplicity of infection was not likely to effect the results
because I have shown in experiments with wild-type VSV that inhibition of infectious
particle production occurs at a moi of 0. 1 (data not shown). Since this treatment was
shown to inhibit viral transcription in cells infected with wild-type VSV (Figure 16B
lane 2) and few infected cells were available for analysis , the abilty of anti-VSV to
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inhibit transcription from this virus was assessed by RT-PCR. RNA from equivalent
numbers of cells in each group was subjected to an RT reaction using oligo-dT primers.
Serial ten-fold dilutions were then made of each RT reaction and subjected to PCR using
primers for VSV M or actin to determine relative levels of mRA. Amplification of
actin cDNA from these serial dilutions demonstrated that there were essentially
equivalent amounts of this mRNA in the two cell populations , since PCR product was
lost at the same dilution (Figure 17). In contrast, the VSV M PCR product was lost at a
lO-fold lower dilution in anti-VSV IgG treated cells compared to NMS IgG treatment
(Figure 17 A , 10- vs. 10. for 35 cycles or 17B , 10. vs. 10- for 20 cycles), demonstrating
inhibition of VSV transcription by antiviral antibody in the absence of de novo VSV G
synthesis.
This result supports the idea that VSV G from input virions is stable in cells
infected with ilG-HA VSV , and that antibody recognition of this protein is sufficient for
inhibition of viral transcription. There is , however, another potential explanation for this
result. The anti- VSV IgG preparation presumably contains antibodies to other viral
proteins; thus , it may be that these antibodies, and not those specific for VSV G, are
responsible for the inhibition of viral transcription seen. This is an interesting possibilty
since VSV G is the only viral protein expressed on the surface of infected cells; any
mechanism invoking other specificities would require intracellular inhibition of virus
replication by antibodies. Sendai virus and rabies virus replication can be inhibited by
antiviral IgA and IgG respectively; it has been suggested that these antibodies enter
infected cells and directly inhibit intracellular virus replication (190 , 191). Thus, it is
,It-
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possible that anti VSV antibodies inhibition virus replicatio in B cells by this
mechanism. More detailed experiments with monoclonal antibodies specific for VSV
proteins wil be required to determine if antibodies recognizing VSV G inhibit viral
transcription if ilG-HA VSV infected B cells.
.-:
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Figure 17. Inhibition of transcription from ilG-HA VSV by anti- VSV
IgG. B cells from bcl-2 tg mice were infected with ilG-HA VSV at
moi=O. l and cultured for 7d in the presence of NMS IgG or anti-VSV
IgG at 10 g/ml. RNA was prepared from each cell population and
subjected to RT-PCR using oligo-dT primers in the RT reactions and
either VSV M or actin primers in PCR reactions as described in Materials
and Methods. The dO sample is RNA from cells harvested immediately
after infection; random primers were used in the RT reaction for this
sample. PCR products were run on 2% agarose gels and detected by
ethidium bromide staining. A. Nested PCR for VSV M (35 cycles per
round), one round of PCR for actin (35 cycles). B. Nested PCR for VSV
M (first round , 35 cycles; second round 20 cycles) and one round of PCR
for actin (35 cycles).
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Chapter v: Discussion
Model of VSV persistence in B cells in vivo
Many RNA viruses are capable of establishing persistent infections which are
often associated with disease (2). Virus persistence has been studied extensively using 
vitro culture systems; however, the mechanisms by which these viruses persist in vivo are
not well understood. Persistent infections of lymphocytes are particularly important
since these types of infections are often associated with immunodeficiency (9).
Furthermore , lymphocytes are an ideal reservoir for RNA viruses such as VSV because
they are non-permssive for virus replication when resting, but support full virus
replication upon activation (32-36). This would allow virus to be maintained in resting
lymphocytes so as to evade the immune response and at the same time provide the virus
with opportunities to periodically reactivate to reinfect new cells or be transmitted to new
hosts. In this chapter, an in vivo model system for studying persistence of a negative-
stranded RNA virus (vesicular stomatitis virus) is described, and a role for antiviral
antibody in the maintenance of virus persistence is proposed.
Based on the data presented in this chapter, I propose the model for VSV
persistence in B cells in vivo depicted in Figure 18. This model shows events that likely
occur during the course of an infection with virus as opposed to after adoptive transfer of
infected cells. When virus enters the body, it encounters both permssive cells (activated
lymphocytes and other cells) and non-permssive cells such as resting B cells. Infected
resting B cells express low levels of viral genome and mRA with little or no de novo
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protein expression;- these resting B cells maintain viral RNA for an extended period
without producing infectious virus. A fraction of the B cells may also undergo
homeostatic proliferation , drving the production of viral antigens in these cells. Viral
antigens produced by these cells and other permissive cells , in turn , induce an antibody
response to the virus. The cells producing viral antigens may eventually be killed by the
virus or by virus specific CTL; alternatively, virus replication might be inhibited by
antiviral antibody. The non-dividing cells , on the other hand, contain only viral genome
mRNA , and perhaps proteins at low levels; these cells are the reservoir for virus during
persistence. Virus persistence is maintained not only by the restriction of virus
replication in resting B cells, but also by antiviral antibody, which can suppress virus
reactivation from these cells. By this model , one would predict that reactivation should
occur when antibody titers drop and when infected B cells are induced to proliferate by
homeostatic signals or during a response to antigen.
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Figure 18. Model for VSV Persistence in B Cells in vivo
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VSV infected, resting B cells contain low levels of viral genome and mRNA , little
or no de novo protein expression , no detectable infectious virus during persistence 
vitro (35, 36). The idea that VSV is maintained in a quiescent state in B cells in vivo 
supported by the finding that viral RNA can be detected for at least 72 days in infected B
cell recipients in the absence of infectious paricles (Table 1). In addition, CFSE stained,
infected B cells can be seen by FACS at day 10 after transfer, and these cells are positive
for VSV M RNA by RT-PCR (Figures 8 and 9). This demonstrates that infected B cells
are not cleared by the immune response or killed by virus , and that viral RNA is
maintained in B cells.
In these experiments , the infected B cells are transferred into B cell deficient xid
recipients , so some of them undergo homeostatic proliferation (Figure 10) as described in
Chapter III. The idea that homeostatic signals induce virus expression in B cells is
supported by three observations: first, proliferation of VSV infected B cells is associated
with virus production in vitro (36); second , RT-PCR analysis demonstrates viral RNA in
recipient cells, suggesting that infectious virus was produced by the donor B cells; third, a
robust antibody response is generated after transfer of VSV infected B cells even when
extracellular virus is neutralized with anti-VSV serum before transfer; this further
suggests that viral proteins or infectious virus were produced by some of the infected B
cells.
While these data are consistent with the idea that viral antigens are produced by
proliferating infected B cells after transfer, the hypothesis needs to be directly tested. 
vitro, the induction of B cell proliferation is associated with optimal expression of viral
1 \
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mRA , genome , protein, and infectious paricles (36). Thus, one prediction is that viral
mRA levels , protein levels, or production of infectious virus should increase in B cells
undergoing homeostatic proliferation. While infectious virus has not been detected in
recipients of infected B cells , it should be possible to develop assays to measure relative
levels of viral mRA or protein in adoptively transferred B cells. One approach would
be to FACS sort CFSE stained donor cells into divided and undivided fractions and
perform quantitative RT-PCR on the two populations. Viral protein levels in the two
populations could be compared by performng Western blots on the sorted populations;
alternatively, viral protein levels in individual cells (either divided or undivided) could be
determined by flow cytometrc analysis.
Another prediction of this hypothesis is that the antibody response seen after
adoptive transfer of infected B cells should be reduced or absent when homeostatic
proliferation is limited. Homeostatic proliferation is greatly reduced in normal , B cell
sufficient recipients and in xid donor B cells (Chapter III). Thus , adoptive transfer of
infected xid B cells into normal unirradiated recipients should reduce or eliminate the
antibody response to VSV if homeostatic proliferation is required. The data presented in
Chapter III suggest that the signals for homeostatic proliferation and those for survival
are distinct; this is demonstrated by the fact that B cells from nfkb1- mice, which have
impaired survival in vivo proliferate in B cell deficient hosts. Thus , an alternative
hypothesis is that survival signals induce virus expression. In this case , homeostatic
proliferation would not be required for induction of viral mRNA, protein, or infectious
virus in adoptively transferred B cells. It is also possible that survival signals and
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proliferation signals induced different stages of virus replication; this would be consistent
with in vitro studies in which VSV replication in resting B cells is differentially regulated
by varous B cell activators (36). Since NF-KB 1 deficiency selectively effects survival
signals , it would be interesting to see how virus expression is regulated in B cells from
nfkb1- mice in vivo. Together, these experiments should determne if lymphocyte
homeostatic signals (survival or proliferative) can induce virus expression in infected B
cells.
The model shown in Figure18 proposes that VSV persistence in B cells is
maintained not only by restrcted virus replication in resting B cells , but also by the
suppression of virus reactivation by antiviral antibodies. Support for the latter
mechanism comes from the observation that prolonged treatment of infected, resting B
cells with anti- VSV antibodies in vitro inhibits virus reactivation in a reversible manner
(Figure 13A and C). The fact that virus suppression is reversible is a key point , because
it means that virus reactivation in vivo is possible , which in turn allows for occasional
infection of new cells in the host or transfer to new hosts. Experiments performed to date
have failed to reactivate virus from infected B cells maintained in vivo. Since type I
interferons do not seem to playa role (see Results), I have performed preliminary
experiments to determine if antiviral antibody suppresses virus reactivation in vivo.
Passive transfer of VSV immune serum suppresses the endogenous antibody response
normally seen in infected B cell recipients (data not shown). Under these conditions
infected B cells are exposed to antiviral antibody, but antibody secreting cells are not
generated. Thus , spleen cells from these recipients can be transferred into secondary
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recipients without transferrng antiviral antibody; this is analogous to the in vitro
experiments in which the anti- VSV antibody can be washed out of the cultures. When
infected B cells are maintained in secondary recipients in the absence of anti- VSV
antibody for 7- 14 days, virus reactivation (by activation of spleen cells in vitro 
adoptive transfer into susceptible IFNa/ mice) is not seen. The most likely
explanation for this is that the recovery period after antibody exposure was not sufficient.
In vitro, reactivation of infectious virus after antibody treatment is only seen in some
experiments after a 7- 14 day recovery period (Table 5), suggesting that recovery periods
of more than two weeks may be necessary. Thus , while the in vitro data are consistent
with the idea that anti-VSV antibodies restrict virus reactivation from B cells in vivo
further experiments are required to demonstrate this directly.
Another consideration in this model is the fate of the infected B cells that
proliferate. It is proposed that these cells express viral antigens or produce infectious
particles; thus, one might argue that these cells should be killed by virus replication or
virus specific CTL. The data suggest, however, that these proliferating cells are
maintained in infected B cell recipients for at least 14 days. One possibilty is that some
of the cells that proliferate after transfer were never infected in culture; thus , infected
cells that proliferated are killed by virus or CTL while uninfected cells that proliferated
remain. This question could be addressed by sorting the cells that have divided and
performing RT-PCR to detectVSV RNA. Assuming that the proliferating B cells are
infected and expressing viral antigens, how might these cells be maintained? A likely
explanation is that infected B cells that proliferate produce infectious virus early after
Jt,
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transfer, but tl;is virus replication is suppressed by innate or specific immune responseS at
later times in a way that preserves these cells; this might be accomplished by antiviral
cytokines such as interferons (192) or by antiviral antibody as described in this chapter.
The role of interferons could be tested by seeing if proliferating, infected B cells are
maintained when the cells are unresponsive to type I interferons by using B cells from
IFa/ R"/. mice. If type I interferons are required to maintain the proliferating cells , then
only non-dividing B cells should be seen after adoptive transfer of infected IFNa/ R"/. 
cells. The requirement for antiviral antibody in maintaining these proliferating B cells
wil be more difficult to determne. The obvious experiment would be to perfonn
transfers into recipients that are incapable of makng an antibody response (such as SCID
mice); these recipients , however, would quickly succumb to the virus , making analysis of
the transferred cells difficult. Another approach would be to see if treatment with anti-
VSV antibodies during activation of acutely infected B cells in vitro enhances the
survival of proliferating infected cells. Clearly, further experiments are required to show
that proliferating B cells are infected and to determne how they are maintained.
Model for the inhibition of VSV reactivation from B cells by anti- VSV antibodies
In the model depicted in Figure 18 , it is proposed that antiviral antibodies act
directly on infected, resting B cells to suppress virus reactivation. This is demonstrated
in vitro by the fact that'reatment of infected B cells with anti- VSV serum for 7 days
inhibits virus replication after activation of the cells with anti-Ig+IL-4 (Figure 13A).
Antibody inhibition is not due to blocking of virus entry since cells treated with antibody
for two days can be activated to produce virus. Rather, inhibition is associated with
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longer term (7 days) antibody treatment (Figure 13A). Treatment of VSV persistently
infected cell lines with antiviral antibodies can result in curing of virus from the cells (22
25); in these cell lines , persistence is maintained by continual reinfection of cells and
antibody blocks the spread of virus in the cultures. Four pieces of evidence argue against
curing in primary B cell cultures. First, there is little if any infectious virus produced in
cultures of primar resting B cells (M. Schmidt, manuscript in preparation), suggesting
that continual reinfection of cells is not required to maintain persistence. Second , a
nonneutralizing monoclonal antibody to VSV G is capable of suppressing infectious virus
production (Figure 14B); this antibody, by definition , cannot block reinfection. Third
viral genome is maintained in antibody treated cells even when viral mRAs , proteins,
and infectious virus are undetectable (Figure 16B , lanes 2+5). Fourth, virus can be
reactivated from antibody treated cells after culturing the cells in the absence of antiviral
antibodies for 7-14 days in some experiments (Figure 13C).
Another possibility is that antibody treatment of infected B cells suppresses B cell
activation in general by Fc-mediated inhibition. Cross-linking of Fcy receptor inhibits
anti-immunoglobulin induced B cell activation at several levels including blastogenesis
DNA synthesis c-myc mRNA induction , and antibody secretion (182- 184). Thus , it is
possible that simultaneous binding of VSV G and Fc receptors on the cell surface by
antiviral antibodies mediates inhibition of B cell activation when the cells are treated
with anti-Ig+IL-4. One argument against this hypothesis is that IL-4 overcomes Fc-
mediated inhibition of B cell activation (185 , 186); indeed, infected, anti- VSV treated
cells proliferate in response to anti-Ig+IL-4. One might argue , then , that an inhibitory
111
142
signal is generated through Fc receptors that specifically inhibits virus replication without
affecting proliferation. The observation that F(ab')2 fragments of anti- VSV lacking the Fc
region inhibit virus reactivation as well as intact antibody, however, further demonstrates
that a signal through the Fc receptor is not required.
The model I favor for VSV reactivation from B cells by antiviral antibody is in
Figure 19. When VSV enters resting B cells , little if any de novo protein synthesis
occurs , but VSV G protein from the virion is stable in the cell and may be found on the
surface. Alternatively, low levels of VSV G may be synthesized and exported to the cell
surface. VSV G interacts with an unknown protein at the cell surface that has signaling
properties. When antibody binds to G, intracellular signals are generated that inhibit
pathways required to support VSV replication in B cells; the "strength" of the signal
determnes which stage of replication is suppressed and the degree of inhibition. When
the B cells are subsequently activated, these pathways are unavailable , and the virus
cannot replicate despite the presence of viral genome in the cells. This suppression of
virus replication is not permanent because virus can be reactivated from the cells after a
recovery period in the absence of antiviral antibody. This model explains how antiviral
antibody can inhibit subsequent virus reactivation in resting B cells , in which VSV does
not actively replicate and it provides for the periodic reactivation of virus from the cells.
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Figure 19. Model for inhibition of VSV replication by anti- VSV antibodies
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The idea that VSV G from input virions is sufficient to mediate suppression by
antiviral antibody is supported by the observation that VSV M mRNA is reduced about
lO-fold by anti- VSV IgG treatment in resting B cells infected with VSV ilG-HA (Figure
17); in cells infected with this virus , G protein can only be derived from input virions.
This is an important point because resting B cells do not produce detectable levels of
VSV proteins (35, 36). Thus , the fact that virion derived G is sufficient for antibody
inhibition provides a source of protein in resting B cells. This does not rule out, however
that in resting B cells infected with wild-type VSV, a small amount of VSV Gis
synthesized de novo and contributes to the pool of protein recognized by antiviral
antibodies. It merely suggests that de novo synthesis is not absolutely required. Since
anti- VSV IgG, which presumably contains antibodies specific for other viral proteins
was used in this experiment, further experiments with monoclonal antibodies to VSV G
wil be required to show that recognition of G suppresses VSV transcripts in VSV ilG-
infected B cells.
What is the evidence that virus suppression is mediated by signals generated by
antibody binding to VSV G? Treatment of infected B cells with anti-VSV serum or IgG
purified from suppresses VSV genome, mRA, protein , and infectious paricle
production (Figure 15A and B , lane 2; Figure 16A and B , lane 2). Since these
preparations likely contain antibodies specific for all of the viral proteins , it is possible
that the functions of multiple viral proteins are directly inhibited by antibody binding.
The fact that a monoclonal antibody specific for VSV G also inhibits all levels of virus
replication (Figure 15A and B , lane 4), however , is not consistent with this idea.
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Inhibition of VSV G function should only affect assembly or release of infectious virus
not transcription or protein synthesis. This suggests that antiviral antibody does not act
by directly inhibiting the function of viral proteins , but rather it interferes with cellular
signaling pathways required for VSV replication in B cells by generating a signal through
VSV G. In the measles virus system, it has been proposed that when antibodies to
measles HA bind the protein on the surface of infected cells, a signal is generated in the
cell that suppresses viral proteins inside the cell (79). Treatment of measles virs
infected rat C6 glioma cells with measles antiserum or a monoclonal antibody to the viral
glycoprotein HA results in the breakdown of phosphatidylinositide (187), suggesting that
the measles HA protein is coupled to cellular signaling molecules. Therefore, it is
reasonable to hypothesize that antibody binding to viral proteins on the cell surface
generates an intracellular signal.
VSV G has a short cytoplasmic domain of 29 amno acids (17); a protein data
base search did not reveal any signaling motifs in this domain , making it unlikely that G
has any direct capacity for signaling. A more likely explanation is that G interacts with a
cellular signaling molecule (shown as "X" in the model) either in the cytoplasm or on the
plasma membrane; it is proposed in the model that binding of antibody to G generates
signals indirectly through this cellular protein. VSV G is thought to interact with VSV M
protein through its cytoplasmic tail (17), so it is not unreasonable to think that G could
interact with cellular proteins as well. Demonstrating interactions between G and cellular
proteins might be difficult in resting B primary B cells because protein levels are likely to
low in these cells. An alternative would be to overexpress G in these cells using an
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adenovirus vector. A mouse transgenic for the human coxsackie/adenovirus receptor
(hCAR) has been developed in this laboratory that allows for the expression of foreign
genes in primary lymphocytes (193). Thus, it might be possible to infect resting B cells
from the hCAR mice with a VSV G expressing adenovirus and then perform
coimmunoprecipitation experiments to determne which cellular proteins G interacts with
in resting B cells.
While I have not presented direct evidence for signals induced by antiviral
antibodies suppress virus reactivation, there is some evidence to suggest that this is the
case. It is important to remember that in these experiments, infected, resting B cells are
being treated with antiviral antibodies; in these cells, VSV replication is restrcted such
that only low levels of viral genome and mRNA are present (35 36). Since the antiviral
antibody treatment acts on resting B cells, it is unlikely to directly inhibit virus
replication. VSV replication is regulated at multiple levels in primary B cells, and
different cellular signaling pathways likely regulate each stage of virus replication (36).
For example , the transcription and genome replication of VSV is regulated by
phosphorylation of the viral P protein by cellular protein kinases (194). I propose that the
putative signals generated by anti- VSV antibody in infected B cells inhibit cellular
signaling pathways required for VSV replication so that these pathways are unavailable
after cell activation.
By analogy with antigen receptors , in which the strength of signal has different
functional consequences (189), one might predict that the level at which virus replication
is inhibited depends on the strength of the putative inhibitory signal(s) generated by
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antiviral antibodies. The strength of signaling through antigen receptors depends on the
concentration of antigen and the avidity of binding; high concentrations of antigen and
multivalent binding generate stronger signals (189). Differential effects on virus
replication are seen in an experiment comparing intact anti- VSV IgG, F(ab' h fragments
and Fab fragments, which presumably have different capacities to generate a signal. 
Table 4 , it is proposed that high concentrations of bivalent antiviral antibody (intact or
F(ab' )2 fragments) generate a strong signal, low concentrations of bivalent antibody or
high concentrations of monovalent (Fab fragments) generate a weaker signal , and low
concentrations of monovalent antibody generate no signal. When a "weak" signal is
generated, only infectious virus production is suppressed completely. Viral RNA levels
are reduced to a much greater extent with a "strong " signal than with a "weak" signal. In
contrast, viral protein levels are only suppressed by a "strong" signal. These data are
consistent with the idea that inhibitory signals are generated by treatment of infected B
cells with antiviral antibody and that the "strength" of signal determnes the level of
suppressIOn.
The hypothesis that interactions between viral proteins and antiviral antibodies
generate inhibitory signals in infected B cells is testable in several ways. It is proposed
that these inhibitory signals interfere with cellular activation pathways required for VSV
replication in B cells. Infected B cells in which virus reactivation is suppressed by
antiviral antibody proliferate in response to anti-Ig+IL-4 and other B cell activators,
suggesting that pathways leading to proliferation are not blocked. B cell activation
however, is associated with numerous other events such as changes in surface marker
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expression and differentiation to effector function that depend on different components of
activation pathways (195). Thus, it would be interesting to see if treatment of infected B
cells with antiviral antibody inhibits anti-Ig+IL-4 induced differentiation to antibody
secretion or upregulation of B cell activation markers such as MHC class II, CD25
CD69 , B7- , and B7-2 (126). Stimulation of B cells through the antigen receptor induces
numerous signaling events; activation of protein tyrosine kinases such as Lyn, Syk, and
Btk; induction of the PLCy, Ras, and PI3-kinase pathways; induction of Ca + flux;
translocation of nuclear transcription factors such as NF-KB (196). If the hypothesis that
antiviral antibody treatment leads to selective inhibition of cellular signaling pathways is
true, it should be possible to see changes in one or more of these signaling events. The
system proposed for looking at interactions of VSV G with cellular proteins might also be
useful for studying the signaling potential of G. Thus , VSV G could be over expressed
from an adenovirus vector in resting B cells from hCAR mice. The effect of cross-
linking VSV G on B cell activation pathways could then be determned by looking the
induction of activation markers and the activity of signaling mediators as described
above.
Summary
The data presented in this chapter describe a powerful model system for studying
the complex mechanisms by which RNA virus persistence is established and maintained
in lymphocytes in vivo. The abilty of lymphocytes to support virus persistence depends
on the interplay between lymphocyte homeostatic signals , which tend to induce virus
expression, and the specific immune response (antibody in this case), which tend to
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suppress virus expression. In Chapter I, a model for EBV persistence. in B cells in vivo
was described in which it was proposed that EBV proteins aid in the establishment of
persistence by inducing the differentiation of resting naive B cells into memory cells
which are thought to maintain virus during latency (62). Another viral protein (LMP2A)
is thought to promote the survival of infected memory B cells and to inhibit reactivation
of virus by interfering with BCR signaling (63-66). Thus, this complex DNA virus is
able to manipulate lymphocyte activation and homeostatic signals to establish and
maintain persistence. Since VSV, a simple RNA virus , does not encode such regulatory
proteins , it must take advantage of normal lymphocyte physiology and the immune
response to the virus to establish and maintain persistence. There are , however, some
interesting parallels between the two viruses. VSV can be maintained in a quiescent state
for extended periods in resting B cells in vitro and the evidence suggests that it does so
in vivo as well. While EBV forces the B cell it infects to differentiate into a cell type in
which it can persist, VSV establishes persistence in a cell type that is naturally non-
supportive of virus replication. The end result in both cases is that the virus is maintained
without significant production of viral antigens so that the infected cells evade clearance
by the immune system. The proposed function of EBV LMP2A (inhibition of virus
reactivation) may be played by antiviral antibody in the case of VSV. This comparison
ilustrates how two dissimilar viruses use different mechanisms to accomplish the same
goal; the establishment and maintenance of a persistent infection in resting lymphocytes.
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